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ABSTRACT  
 
This thesis examined whether reactive hyperemia peripheral arterial tonometry (RH-PAT) and 
flow-mediated dilation (FMD), non-invasive measures of peripheral endothelial function, are 
associated with coronary microvascular function following multiple pharmacological stimuli in 
patients with suspected coronary microvascular dysfunction (CMD). Patients with suspected 
CMD completed peripheral vascular assessments using concurrent RH-PAT and FMD, while 
coronary microvascular function was measured using the index of microvascular resistance 
(IMR) and the coronary flow reserve (CFR) during endothelial independent (adenosine), 
endothelial-dependent (acetylcholine), and sympathetically-mediated (dobutamine) hyperemia. 
Any abnormality in the IMR and/or CFR during the adenosine and/or acetylcholine trials defined 
patients with CMD. RH-PAT and FMD were attenuated in patients with CMD (P<0.05). RH-
PAT was correlated with the dobutamine IMR and CFR (P<0.05), while FMD was correlated 
with the adenosine (P<0.05) and acetylcholine IMRs (P<0.05), but not the CFRs. Therefore, this 
thesis suggests that both RH-PAT and FMD can identify patients with CMD in clinical settings.  
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CHAPTER 1.0 GENERAL INTRODUCTION 
 
Patients with exertional chest pain and a positive exercise stress test are routinely referred 
for coronary angiography to assess for obstructive coronary artery disease. The presence of a 
blockage in the coronary arteries often elicits inadequate oxygen delivery to cardiac muscle, 
explaining the observed chest pain. However, when obstructive coronary arteries are not 
observed, physicians are often faced with challenges in determining the cause of chest pain. 
Importantly, the observation of non-obstructive coronary arteries have been apparent since the 
introduction of coronary angiography (1, 2), while more recently, approximately one third of 
patients referred for coronary angiography have no significant coronary obstructions (3).  
 One limitation of coronary angiography is the inability to visualize the microcirculation, 
the compartment of the vascular system that plays an important role in regulating blood flow to 
cardiac muscle (4). In particular, the inability to dilate the coronary microcirculation, a condition 
known as coronary microvascular dysfunction (CMD) (5), is gaining appreciation as a significant 
contributor to increased adverse cardiac events and mortality (6, 7). However, screening patients 
with CMD is clinically challenging, and often results in increased emergency department visits 
and multiple coronary angiographies without reaching a confirmed diagnosis (8, 9). Since the 
procedures required to diagnose patients with CMD are invasive, expensive, and require highly 
trained medical personnel, determining clinically available non-invasive measures to screen this 
cohort is important to help patients with chest pain and non-obstructive coronary arteries reach a 
diagnosis faster.  
 In 1992, the use of ultrasound to measure vascular function in the human arm using a 
technique called flow mediated dilation (FMD) was first reported (10), while later in 2003, 
vascular function was measured in the finger microvasculature using reactive hyperemia 
peripheral arterial tonometry (RH-PAT). However, it is currently unclear if these measures are 
related to vascular function within the coronary microvasculature. The relationship between 
peripheral and coronary vascular function could have important clinical implications and can 
help screen patients with non-obstructive coronary arteries and suspected CMD. Therefore, the 
aim of the current thesis is to determine if vascular function in the coronary microvasculature is 
associated with vascular function in the periphery.  
 
  
2 
 
CHAPTER 2.0 LITURATURE REVIEW 
 
2.1. General Introduction 
The pulsatile nature of blood flow through the circulation is governed by the contracting 
heart. During each heartbeat, the left ventricle propagates blood peripherally to meet the 
metabolic demands of tissue. Myocardial oxygen delivery, however, primarily occurs during 
diastole, as ventricular contraction impedes blood delivery to the myocardium (11, 12). Given 
that cardiac muscle extracts ~70-80% of oxygen from the arterial coronary vasculature, 
augmenting coronary blood flow is the primary mediator of matching myocardial oxygen supply 
to demand, both at rest and during exercise (reviewed by Duncker and colleagues (4)). This is 
accomplished by both increases in perfusion pressure and reductions in coronary resistance (4). 
In 1971, Holmberg and colleagues noted that the reduction in coronary resistance primarily 
facilitated the increase in coronary flow during cycle ergometer exercise (13). Further, coronary 
resistance decreases during exercise by ~20-30% in humans (14), accounting for ~90% of the 
coronary vasculature’s ability to augment blood flow (4).  
Matching myocardial oxygen supply and demand through changes in coronary resistance 
fundamentally relies on healthy functioning coronary arteries. In 1989, Gordon and colleagues 
examined the epicardial coronary vasomotor response to supine cycle ergometer exercise in 
participants with healthy and diseased coronary epicardial vessels (15). In healthy epicardial 
coronary arteries, the response to exercise was vasodilation, however, in arterial segments with 
epicardial stenosis (i.e. vessel narrowing), the response to exercise was vasoconstriction (15). In 
chronically instrumented dogs, experimentally attenuating endothelial function independent of 
coronary stenosis, also caused epicardial coronary vasoconstriction during treadmill exercise 
(16). These concepts highlight the importance of vascular health in mediating the appropriate 
vascular responses to increased metabolic demand (i.e. exercise) in order to adequately match 
myocardial oxygen supply to demand. 
 
2.2. Understanding Blood Flow in the Circulation 
2.2.1. Blood Vessel Anatomy 
Blood vessels, viscoelastic in nature, are comprised of three layers: the adventitia, media 
and intima (17). The proportion of each vascular layer varies largely throughout the arterial tree, 
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and given that all three layers contain separate viscoelastic properties (18), the stiffness of 
vessels can therefore vary. The adventitia, the outer layer lining blood vessels, is composed 
primarily of collagen and fibroblasts, and contains sympathetic nerve endings that are 
responsible for mediating vasoconstriction (17). The media layer is composed of vascular 
smooth muscle cells (VSMC), as well as collagen and elastin (17). In young healthy humans, 
elastin is predominant compared to collagen, which enables compliant vessels. However with 
aging, collagen content begins to increase (19, 20), concurrently increasing the overall stiffness 
of the vasculature, which can negatively impact myocardial performance (explained in 
subsequent section). Lastly, the intima is composed of endothelium cells, which physically 
contacts adjacent blood flow and is responsible for mediating a range of cellular responses. 
These cellular responses will be discussed in detail in Section 2.3.  
 
2.2.2. Blood Flow in the Macrocirculation 
The arterial circulation can be divided into the macrocirculation (i.e. large arteries, and 
conduit arteries) and the microcirculation (i.e. arterioles) (17). Large arteries are primarily 
composed of elastin, thus facilitating high compliance (21). This is important given that the 
primary role of these arteries are to: 1) dampen the magnitude of pressure caused by blood 
ejection from the left ventricle, and 2) store blood within the vessel during systole and expel it 
during diastole (22). Termed the Windkessel function, approximately half of stroke volume is 
propagated peripherally during systole, while the remaining stroke volume is circulated during 
diastole, a process that allows for continuous blood flow through the large vessels (22). Further, 
high central artery compliance decreases left ventricular work (i.e. reduced afterload) (23), and 
increases left ventricular relaxation (24). In an animal model, chronically increasing aortic 
stiffness using aortic bandaging to constrict the aorta, the brachiocephalic trunk and the left 
subclavian artery, resulted in higher resting coronary blood flow relative to control animals (25), 
due to the increased ventricular afterload. 
With aging, increased collagen deposition in both large and conduit arteries increases 
artery stiffness (19, 20), with large arteries being more susceptible to increases in vascular 
stiffness compared to conduit arteries (26). During systole, forward wave pulsation through the 
arterial tree collides at vascular bifurcations systemically, causing pressure wave reflections that 
propagate retrograde to the heart (27). Increases in arterial stiffness impact this process by 
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augmenting both retrograde pressure wave velocity and magnitude, due to less distensibility, and 
therefore less Windkessel effect (20, 28).  This increased wave reflection propagation and 
amplitude causes blood pressure to arrive back at the heart during late systole, opposed to 
diastole, which augments blood pressure and left ventricular afterload (28).  
Conduit arteries, predominantly composed of smooth muscle, actively modulate vascular 
tone and diameter depending on the physiological stressor (28). Fairfax and colleagues observed 
in resting young healthy men that spontaneous sympathetic discharges increased mean arterial 
pressure and decreased vascular conductance in the brachial, femoral, and popliteal arteries (29, 
30). Additionally, increasing metabolic activity (i.e. changes in CO2, O2, lactate, and hydrogen 
ions) can cause conduit arteries to dilate (31). For example, Tremblay and Pyke highlighted that 
rhythmic handgrip exercise elicits an intensity dependent increase in brachial artery diameter 
(31), important for matching blood flow to metabolic demands. Together, these studies 
demonstrate that sympathetic activation can constrict conduit arteries, while exercise can dilate 
conduit arteries in both active and inactive muscles to augment blood flow to match metabolic 
demand. 
 
2.2.3. Blood Flow in the Microcirculation 
Arterioles, primarily composed of endothelial cells and several layers of VSMCs, vary in 
size depending on their proximity to distal capillaries (32). Similarly to conduit arteries, these 
vessels are highly innervated by sympathetic nerve fibers (33, 34), which elicit vasoconstriction. 
Arterioles contain a large capacity to modulate diameter, and therefore total vascular resistance 
and overall blood flow (35). Specifically, increasing metabolic activity can cause arterioles to 
dilate up to 50% of their original diameter (36), leading to a 100-fold increase in blood flow to 
muscles (37). Contrarily, sympathetic stimulation can lead to significant vasoconstriction and 
significantly limit blood flow. In vitro sympathetic nerve stimulation innervating distal arterioles 
and terminal arterioles resulted in ~35% and ~55% reductions in diameter respectively (38).  
During exercise, sympathetic activation and the production of metabolites concurrently 
increase (39), yet have conflicting vascular responses. In order to preserve blood delivery to 
exercising muscles, local metabolites attenuate the response of the sympathetic nervous system 
by a process called functional sympatholysis (40–42). In 1962, Remensnyder and colleagues 
noted that sympathetic stimulation caused vasoconstriction in the dog’s hindlimb at rest, 
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however, the same stimulus during exercise resulted in an attenuated vasoconstrictor response 
(40). Similar findings later found that during dynamic exercise of the hamster retractor muscle, 
distal arterioles were the most sensitive to preserving their diameter upon sympathetic 
stimulation, relative to conduit arteries and proximal arterioles (41). In humans, Tschakovsky 
and colleagues investigated the process of functional sympatholysis by infusing a low, medium, 
and high dose of tyramine (i.e. pharmacological sympathoexcitatory agent) into the brachial 
artery during rest, moderate and heavy exercise (42). Tyramine elicited a dose-dependent 
decrease in forearm vascular conductance and flow, while exercise elicited an intensity-
dependent attenuation of the tyramine response. Together, these select studies highlight the 
utility of functional sympatholysis in preserving blood delivery to exercising muscles.  
 
2.3. The Endothelium and Nitric Oxide 
2.3.1. Definition and Discovery 
The endothelium is a single layer of cells that lines the inside of blood vessels 
systemically (43) and physically interacts with adjacent blood flow (44). The endothelium has 
the capacity to synthesize and release a variety of substances, however, one of the most potent 
substances aiding in the maintenance of overall vascular health is nitric oxide (NO). NO has been 
extensively researched since its discovery in 1980 by Robert F. Furchgott and John V. Zawadzki 
(45). In their seminal experiment, Furchgott and colleague noted that acetylcholine-induced 
dilation of the rabbit abdominal aorta was abolished following removal of the endothelial cells, 
but not removal of the tunica adventitia, suggesting that the interaction between the endothelial 
cells and acetylcholine caused the release of a substance not fully identified (45). Initially termed 
endothelial-derived relaxing factor, the substance was later identified in 1987 as NO (46, 47).   
 
2.3.2. Synthesis of Nitric Oxide 
Nitric oxide (NO) is a soluble gas with a half-life of ~6-30 seconds (48), and is 
synthesized by a family of nitric oxide synthases (49). In particular, NO is synthesized in the 
endothelium primarily by the enzyme endothelial nitric oxide synthase (eNOS), located in 
specialized folds within the endothelial cell membrane, termed caveolae  (48, 50–52). Influx of 
calcium into endothelial cells causes the displacement of the protein caveolin-1 from calmodulin, 
activating eNOS, and subsequently leading to the synthesis of NO from the precursor L-arginine 
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(51). Further, several co-factors are involved in the conversion of L-arginine to NO, including 
tetrahydrobiopterin, and nicotinamide adenine dinucleotide phosphate (50).  Intracellular 
endothelial NO then diffuses out of the endothelium and into the VSMCs, where it activates 
guanylate cyclase, the enzyme responsible for the conversion of guanosine triphosphate into 
cyclic guanosine monophosphate (50). Cyclic guanosine monophosphate causes smooth muscle 
relaxation by decreasing intracellular calcium, ultimately leading to vasodilation (50).  
 
2.3.3. Endothelial Function and Dysfunction 
NO synthesized and released from endothelial cells plays a large role in mediating 
vasodilation (48, 51). However, NO possesses further functions that help maintain vascular 
health, including the prevention of thrombosis formation (53–56), anti-inflammatory properties 
(53, 54), maintenance of blood pressure (57, 58), and limiting VSMC proliferation (59). 
Specifically, NO has been shown to inhibit key leukocyte adhesion molecules including vascular 
cell adhesion molecule-1 and intracellular adhesion molecule-1 in vitro (53) and in vivo (54, 56), 
in addition to limiting platelet deposition (55). Further, administration of the NO inhibitor N-
monomethyl-L-arginine (L-NMMA) to anesthetized rabbits caused an increase in mean arterial 
pressure (58), indicating that NO plays a role in maintaining blood pressure. Exogenous nitrate 
consumption (i.e. beetroot juice extract) has also been shown to acutely decrease blood pressure 
in normotensive subjects (60). Lastly, several studies have highlighted that the endothelium and 
the sympathetic nervous system can interact and have a bidirectional effect on one another (61–
65). For instance, nitric oxide blockade in young healthy humans caused an increase in 
sympathetic nerve activity (66), while sympathetic blockade with trimethaphan acutely improved 
the forearm blood flow responses to acetylcholine in obese hypertensive participants (67). 
The endothelium releases a variety of additional factors that possess divergent effects on 
vascular health. For instance, prostacyclin, bradykinin, and endothelium-derived hyperpolarizing 
factor (EDHF) supplement NO in mediating vasodilation and inhibiting platelet aggregation (51, 
68). Contrarily, endothelin-1 (ET-1) and thromboxane A2 can stimulate vascular constriction and 
facilitate atherosclerotic plaque development (51, 68). Specifically, increased resting ET-1 often 
observed in patients with cardiovascular disease (CVD), can promote vascular inflammation and 
oxidative stress (69, 70). 
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In a healthy endothelium, there is a balance between vasodilator and vasoconstrictor 
factors produced, with sufficient basal production of NO mediating normal vascular responses 
(43). However, in dysfunctional endothelial cells, NO bioavailability becomes attenuated, while 
concurrent increases in vasoconstrictors and pro-inflammatory substances are produced by the 
endothelium (43). As traditional cardiovascular risk factors develop and progress, dysfunction of 
the endothelium increases with the gradual accumulation of inflammation and oxidative damage 
(71), which attenuates NO bioavailability; since NO must be redirected to scavenge free radicals 
(48). In support of this, endothelial function is attenuated in subjects with diabetes (72, 73), 
hypercholesterolemia (10, 74), hypertension (75), and smokers (76). Further, Celermajer and 
colleagues noted a strong negative correlation between endothelial function and the number of 
traditional cardiovascular risk factors in 500 apparently healthy subjects (77). Hashimoto and 
colleagues observed similar findings in 101 patients with one or more traditional cardiovascular 
risk factors compared to 40 control subjects (78). These studies highlight that traditional 
cardiovascular risk factors may influence endothelial dysfunction due to the accumulation of 
inflammation and oxidative damage, while the number of risk factors can further attenuate 
vascular function.  
 
2.3.4. The Role of Shear Stress on Endothelial Function 
Shear stress, defined as the frictional force between endothelial cells and adjacent blood 
flow (79), is the main stimulus for the release of NO (44, 80). Shear stress is proportional to the 
product of blood viscosity and blood velocity relative to arterial diameter (i.e. Shear stress = 
viscosity x velocity/diameter) (81). Viscosity is typically not measured and therefore assumed to 
be a constant of 4 for small arteries (82), such as the brachial artery. Shear stress causes the 
activation of a large number of mechanoreceptors located on endothelial cells (44, 80), which 
mediates the influx of calcium and subsequent signalling cascade resulting in NO production and 
vasodilation.  
The magnitude and type of shear stress can modulate endothelial cell function and 
morphology, having large implications on atherosclerotic development (80, 83). Given the 
pulsatile nature of blood flow, the arterial tree experiences pulsatile shear stress, defined as high 
unidirectional shear stress with varying magnitudes (44). High shear stress can increase 
production and synthesis of NO, and upregulate endothelial transcription factors that positively 
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influence cell function (44). However, regions of the vasculature containing curves and 
bifurcations can experience oscillatory shear stress (i.e. multidirectional shear stress containing 
both positive and negative periods of shear stress over the cardiac cycle (44)) and/or low 
endothelial shear stress. In experimental models of the human carotid arteries, Ku and colleagues 
noted large oscillatory shear stress patterns in the internal carotid artery, which was strongly 
correlated to plaque deposition (84). Further, while experimentally inducing an acute stimulus 
designed to attenuate resting endothelial shear stress in the human forearm, Thijssen and 
colleagues observed a reduction in endothelial function (85). Animal studies suggest that chronic 
exposure to oscillatory and low endothelial shear stress can upregulate gene expression of 
pathways that ultimately increase oxidative damage, inflammation, and thrombosis (44). Thus, 
the type and magnitude of shear stress can play an important role in affecting acute and chronic 
adaptations to endothelial cell function and morphology.  
 
2.4. Measures of Vascular Function  
2.4.1. Flow Mediated Dilation 
2.4.1.1. Definition and Discovery 
First reported in the Lancet in 1992 by David S. Celermajer and John E. Deanfield, flow 
mediated dilation (FMD) is defined as the dilation of a blood vessel following a period of 
increased blood flow (i.e. hyperemia). The stimulus most commonly used to elicit a hyperemic 
response is 5 minutes of forearm ischemia (86). This test is utilized to assess endothelial 
function, given that hyperemia (i.e. shear stress) increases NO production (described in detail in 
former section). The procedure of these measures will be described in depth in Section 3.3.2.  
 
2.4.1.2. Physiology of FMD 
Forearm ischemia and subsequent reperfusion induces a hyperemic response that largely 
increases endothelial shear stress (81). Given the downstream signalling cascade previously 
described, several studies have evaluated the contributions of NO to the FMD response. 
Joannides and colleagues were the first to investigate the hyperemic dilatory response of the 
radial artery following infusion of the NO inhibitor L-NMMA (87). The radial artery had a 
normal dilatory response to hyperemia, however, following L-NMMA infusion, the radial artery 
constricted following hyperemia (87). Mullen and colleagues also observed that L-NMMA 
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completely abolished the FMD response of the radial artery (88). Investigating the dilatory 
response in the brachial artery, a more recognized approach to measuring the FMD response 
(86), showed similar results to Mullen and colleagues, such that L-NMMA completely abolished 
the FMD response following wrist occlusion (89). Further, measures from the brachial artery 
after forearm occlusion (the most standardized protocol for assessments of FMD) in participants 
that were young healthy (90), old healthy (91), and smokers (92), showed that L-NMMA 
attenuated the FMD response, but was not completely abolished. Lastly, a meta-analysis of 20 
studies that included over 300 participants revealed that NO-inhibition blunted the FMD 
response by ~70% (93), highlighting that FMD is highly NO mediated.  
 
2.4.1.3. Clinical Relevance of FMD 
Several longitudinal cohort studies have assessed the capacity of FMD to predict the  
incidences of, and mortality attributed to, CVD (94–99). These studies have been conducted in 
population-based cohorts of apparently healthy individuals (98, 99), post-menopausal women 
(97), patients with chest pain (95, 96) and patients with coronary artery disease (94). In all 
populations, FMD was a strong predictor of cardiovascular events and mortality (100). These 
findings remain, regardless of the methodology employed (i.e. proximal or distal cuff location, 
varying ischemic time, etc.) (101). Taken together, FMD for the assessment of vascular function 
can strongly predict population risk of CVD, highlighting its relevance within clinical settings, 
and may therefore provide additive value to traditional risk factors for clinicians.  
 
2.4.2. Reactive Hyperemia Peripheral Arterial Tonometry 
2.4.2.1. Definition and Discovery 
Reactive hyperemia peripheral arterial tonometry (RH-PAT) is a novel non-invasive 
method of measuring endothelial function. RH-PAT was first utilized by Robert P. Schnall and 
Peretz Lavie in 1999 to investigate obstructive sleep apnea. However in 2003, Jeffrey T. Kuvin 
and colleagues were the first to utilize this novel assessment for quantification of endothelial 
function (102). During RH-PAT, volume changes within the finger microvessels (i.e. pulse 
amplitude changes) are measured at rest and following a stimulus of ischemia-induced 
hyperemia, similarly to that of FMD. Then, the reactive hyperemia index (RHI) is calculated 
based on the hyperemic pulse amplitude relative to the baseline amplitude (discussed in further 
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detail in Section 3.3.2.). The natural log transformation of the RHI (LnRHI) is also calculated, as 
the monotonic transformation is more normally distributed compared to the RHI (103).  
 
2.4.2.2. Physiology of RH-PAT 
Resting digit blood flow is primarily regulated by the sympathetic nervous system (104), 
while NO seems to play a smaller role in maintaining resting microvascular tone (104, 105). 
Currently, there is limited data investigating the mediators of the dilatory response during RH-
PAT. Nohria and colleagues (106) examined the effect of NO inhibition on RH-PAT, and 
demonstrated that L-NMMA infusion into the brachial artery attenuated the RHI by ~46%, 
indicating that NO plays a significant role in the microcirculatory hyperemic response. Other 
factors are likely to facilitate this response given that >50% of the hyperemic response remained. 
Further, NO inhibition also had no effect on resting pulse amplitude (106), confirming earlier 
studies that basal NO plays a minor role in regulating resting fingertip flow (104, 105).  
 
2.4.2.3. Clinical Relevance of RH-PAT 
RH-PAT has been shown to aid clinicians in risk prognosis in apparently healthy patients 
(107), and patients with coronary artery disease (108–110) or chest pain (111, 112). Specifically, 
in patients with unexplained chest pain, Rubinshtein and colleagues (112) observed higher rates 
of adverse events in patients with lower microvascular function, defined by an LnRHI<0.4, 
compared to patients with higher microvascular function following a 7 year follow-up (adverse 
events=48% vs 28%, respectively). Further, in high-risk patients undergoing coronary 
angiography due to chest pain, low microvascular function, defined by an RHI<0.53, also had 
significantly greater incidence of cardiovascular events compared to patients with greater 
microvascular function following a 5 year follow-up (cardiovascular events=32% vs 8%, 
respectively) (111). Both studies support the concept of utilizing RH-PAT as a measure of risk 
prognosis for CVD incidence and mortality. 
 
2.4.3. Comparison of FMD and RH-PAT 
Since both FMD and RH-PAT are non-invasive measures attempting to quantify 
endothelial function, several studies have compared the two measures to determine similarities. 
However, given that both measures are obtained from different vascular sites (i.e. conduit artery 
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vs. microvasculature) and are governed by relatively different contributions of NO (NO 
antagonists abolish the hyperemic responses of FMD and RH-PAT by >70% and <50%, 
respectively (93, 106)), several smaller studies (102, 113), and larger cross-sectional studies 
(114, 115) have highlighted that FMD and RH-PAT are weakly correlated. In a cohort from the 
Framingham Heart Study, Hamburg and colleagues have highlighted how FMD and RH-PAT are 
affected by different risk factors. Specifically, attenuated brachial artery FMD was associated 
with age, higher systolic blood pressure, and BMI, while the risk factors associated with 
abnormal RH-PAT were BMI, cholesterol, diabetes and smoking (114). Although FMD and RH-
PAT are weakly correlated and appear to be influenced by different cardiovascular risk factors, a 
recent meta-analysis concluded that both FMD and RH-PAT equally contain a significant 
predictive value of cardiovascular events (116). Therefore, both FMD and RH-PAT provide 
clinically important information regarding patient risk stratification, regardless of physiological 
differences governing both measures. 
 
2.5. Sex Differences in Cardiovascular Disease 
2.5.1. History and Epidemiology  
In the early 20th century, women were excluded from longitudinal studies, as CVD was 
once considered “a man’s disease” (117). It was not until the 1950’s that women were included 
in longitudinal studies, and subsequent reports indicated that the development of CVD in women 
significantly increased in later years of life, following menopause (118–120). A report from the 
American Heart Association in 2006 highlighted that: 1) CVD was the number one cause of 
death in women 65 years and older, and 2) more women have died from CVD compared to men 
(121). An updated report in 2017 showed that the prevalence of CVD was equal in men and 
women 40 years and older, with greater cardiovascular mortality in women compared to men 
aged 80 years and older (122). Despite this, there is still a lack of clinical trials and overall 
cardiovascular research targeted towards women (123). At both 1 year and 5 years following a 
myocardial infarction, women aged 45 years and older are more likely to die compared to men 
(122), highlighting the need for more research on improving clinical outcomes in women (123).  
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2.5.2. Sex Differences in Vascular Function 
Premenopausal women have a low incidence of CVD compared to aged matched men 
(124). First highlighted by Kannel and colleagues in 1976, the loss of estrogen facilitated by the 
onset menopause was associated with an increase in CVD incidence rates (120). Subsequent 
studies have mechanistically highlighted that estrogen directly influences vascular function 
(125–127). Estrogen directly interacts with two estrogen receptors (ER) in the vasculature: ERα 
and ERβ, located within caveolae on the endothelium (128, 129). Activation of ERs can 
upregulate eNOS gene expression (130) and eNOS activity (131) in vitro; therefore increasing 
NO bioavailability (125, 128, 132, 133). In support of this mechanistic data, pre-menopausal 
women have greater FMD (134, 135) and RH-PAT (135) responses compared to age-matched 
men. However differences within resting brachial artery diameter may largely influence this sex 
difference, since women have smaller brachial arteries compared to men (134, 136). When 
allometrically scaling the FMD response (an analysis method designed to remove the influence 
of baseline diameter (137)) Shenouda and colleagues observed that men actually had a greater 
FMD response compared to age-matched women (138), however, the usefulness of allometric 
scaling is still in debate (139). Further, Heffernan and colleagues noted that women had higher 
RH-PAT responses compared to men, however, when utilizing baseline brachial artery diameter 
as a covariate, this observed sex difference was abolished (140). These results highlight that 
women may have larger dilatory responses compared to men, but this response may be 
intrinsically influenced by baseline brachial diameters, rather than a direct influence from 
estrogen. 
In a cross-sectional design, Celermajer and colleagues investigated the effects of aging on 
vascular function, by conducting FMD assessments on 238 apparently healthy subjects between 
the ages of 15 to 72 years (136). Here, it was observed that FMD declined earlier in life for men, 
following the age of ~41 years, while women had a sharp reduction in FMD occurring later in 
life, at ~53 years of age (136). Interestingly, there was no age related reductions in VSMC 
function, assessed using the endothelial independent dilator glyceryl trinitrate, indicating that the 
age associated reduction in vascular function was specific to the endothelium (136). Similar 
findings were observed in a separate small cross-sectional cohort (141), highlighting that 
menopause mediated declines in estrogen likely attenuate endothelial function rapidly in women, 
while vascular function in men gradually declines with age.  
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2.6. Cardiac Microvascular Dysfunction 
2.6.1. Definition and Discovery 
Since the introduction of coronary angiography for the detection of coronary epicardial 
stenosis, the observation of chest pain (i.e. angina pectoralis) with normal coronary arteries was 
becoming apparent (1, 2). Arbogast and Bourassa in 1973 were one of the first groups to 
highlight the concept of myocardial ischemia despite normal coronary arteries (142). Subjects 
with electrocardiographic evidence of ischemia and normal coronary arteries (Group X) were 
compared with subjects with electrocardiographic evidence of ischemia and coronary artery 
obstruction (Group C) during atrial pacing. The authors observed similar changes in myocardial 
lactate production and myocardial ischemia (determined by ST segment depression on the 
electrocardiogram) in both groups, despite only the latter group having coronary obstruction. In a 
subsequent editorial, Harvey Kemp later termed “group X” as “syndrome X” (143). In 1981, 
Opherk and colleagues demonstrated that syndrome X patients had reduced coronary dilatory 
capacity to dipyridamole (i.e. an endothelial independent vasodilator) and subsequently, 
increased lactate production during atrial pacing compared to controls (144), highlighting that 
the inability of the coronary vasculature to dilate may explain the reduced myocardial blood 
delivery and observed ischemia. Later in 1988, Cannon and Epstein introduced the term 
“microvascular angina” to further describe patients with attenuated coronary flow and increased 
coronary resistance of the microvasculature (145). 
Today, cardiac syndrome X (CSX) and coronary microvasculature dysfunction (CMD) 
are used to describe different patient groups. CSX is used to describe patients with exertional 
angina pectoralis, ST segment depression during exercise stress testing, and angiographically 
normal arteries (defined as <50% epicardial stenosis). CMD is diagnosed in patients with angina 
pectoralis, angiographically normal arteries, and abnormal coronary microvascular vasodilation 
during coronary reactivity testing (described in detail in Section 2.6.4.). 
 
2.6.2. Prevalence  
Approximately 10-30% of chest pain patients undergoing coronary angiography have no 
significant epicardial stenosis (3, 146, 147), while the prevalence of normal coronary arteries is 
higher in women compared to men. The Coronary Artery Surgery Study (CASS) observed that 
11% and 39% of men and women undergoing angiography, respectively, had angiographically 
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normal coronary arteries (148), while more recently, the Women’s Ischemia Syndrome 
Evaluation (WISE) study observed that 62% of women undergoing coronary angiography had no 
significant epicardial stenosis (149). Further, in 2001 the WISE study also demonstrated that 
approximately half of their cohort with chest pain and angiographically normal arteries had 
CMD (150) while Sara and colleagues observed a prevalence of ~66% in a mixed sex cohort 
(151). Originally, the prognosis of CSX and CMD was considered to be benign. However, the 
WISE study has also shown numerous times that CMD is associated with a poor prognosis (6, 7, 
152–154). Specifically, the WISE study observed that abnormal coronary reactivity testing to 
adenosine (7, 154) or acetylcholine (6, 154) was independently associated with adverse 
cardiovascular events. Together, these studies highlight that women have a higher prevalence of 
CMD, a disease associated with a poor prognosis.    
 
2.6.3. Pathophysiology 
Patients with CSX have reduced coronary dilatory capacity and therefore attenuated 
blood delivery to the myocardium, leading to myocardial ischemia (144). Endothelial 
dysfunction is likely central to this abnormal response (155). For example, in patients with 
angiographically normal arteries, intracoronary infusions of L-NMMA caused a reduction in 
distal coronary artery diameter, highlighting that NO plays a role in maintaining basal 
vasculature resistance (156), in addition to facilitating epicardial dilation during scenarios of 
increased metabolic demand, such as atrial pacing (157). Further, there is evidence that 
endothelial dependent vasodilation in CSX has greater dysfunction in microvessels compared to 
epicardial vessels (158). In response to intracoronary acetylcholine infusions, CSX patients had a 
similar epicardial dilatory response compared to controls, however, demonstrated an attenuated 
increase in coronary blood flow (158). Since coronary microvessels primarily mediate 
augmentations in coronary blood flow (13, 14), the impaired coronary blood flow response in 
subjects with CSX suggests impaired microvascular dilation. Subsequent studies by Chauhan and 
colleagues observed both endothelial dependent and independent dilatory dysfunction in a larger 
sample of patients with CSX (159). Indeed, several studies have shown that coronary endothelial 
dysfunction was associated with myocardial perfusion impairments (160, 161). Additionally, 
CSX patients have a reduced brachial FMD response relative to healthy controls, and of a similar 
magnitude with patients with coronary obstruction (162), highlighting how endothelial 
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dependent vasodilation is systemically attenuated. Several other studies have additionally 
observed a reduced brachial artery FMD in patients with CSX (163–166).  
A healthy endothelium regulates the balance between the secretion of vasodilators (i.e. 
NO, prostacyclin, etc.) and vasoconstrictors (i.e. ET-1) (68). As endothelial dysfunction 
progresses, this balance becomes disrupted, with increased release of vasoconstrictors, such as 
ET-1 (43). Indeed, Kaski and colleagues observed higher plasma concentrations of ET-1 in CSX 
compared to controls (167). Given that ET-1 causes vasoconstriction within the coronary 
vasculature (168), it is possible that this may further contribute to the reduced blood delivery to 
the myocardium, and subsequent myocardial ischemia. Together, these data demonstrate that 
endothelial dysfunction likely plays a central role in the microvascular abnormalities observed in 
CSX patients.  
Arterial stiffness, often elevated in patients with CSX compared to healthy age-matched 
controls (169), is another vascular abnormality that can influence the coronary flow response. In 
an animal model, experimentally increasing aortic stiffness using a rigid aortic tube, designed to 
bypass the abdominal aorta, augmented coronary blood flow at rest (170). In humans with 
angiographically clear coronary arteries, subjects with elevated arterial stiffness (as measured by 
pulse wave velocity, augmentation indices (171) or pulse pressure (172)) also had increased 
resting coronary flow (171, 172) and an attenuated coronary vasodilatory capacity (171). Greater 
resting flow would inherently decrease vasodilatory capacity since coronary flow reserve (CFR) 
is calculated as the maximal coronary flow divided by baseline coronary flow (173). Further, the 
WISE study observed a strong negative correlation between arterial stiffness (measured using 
pulse wave velocity and augmentation index) and the coronary vasodilatory capacity in 50 
women with suspected CMD (174). Together, these studies highlight how arterial stiffness can 
attenuate the coronary flow response and increase the susceptibility of the myocardium to 
ischemia.  
 
2.6.4. Diagnosis and Screening 
The assessment of the coronary microvasculature using coronary reactivity testing, which 
involves the quantification of microvascular vasomotion in response to pharmacological 
vasodilation (commonly during an endothelial-dependent and endothelial independent stimuli), is 
required to diagnosis CMD. The most common measure of microvascular function is the 
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coronary flow reserve (CFR), calculated as the ratio of coronary blood flow during 
pharmacological stimulation to coronary blood flow at rest (150). Different modalities can be 
used to evaluate CFR using either non-invasive measures (including cardiac PET scans (175, 
176), cardiac MRI (177–179), and transthoracic or transesophageal echocardiography (180)) or 
invasive measures (intracoronary Doppler flow wire and thermodilution (7, 181)). A variety of 
different endothelial-dependent and independent pharmacological stimuli have been previously 
utilized to elicit hyperemia. For instance, endothelial dependent pharmacological stimuli include 
acetylcholine, bradykinin, atrial pacing, and adenosine triphosphate (6, 155, 157, 158, 182–184), 
while endothelial independent pharmacological stimuli include dipyridamole, sodium 
nitroprusside, and papaverine (154, 155, 159). Adenosine, a mainly endothelial independent 
stimulus in the coronary circulation, is also commonly utilized to assess coronary microvascular 
function (154, 159). Different CFR cut-offs have been utilized to diagnose CMD, ranging from 
<2.5 (150), <2.32 (7, 154) and <2.0 (175) for endothelial independent stimuli, while a CFR cut-
off of <1.5 is generally utilized for endothelial-dependent stimuli (151, 185). Regardless of the 
cut-off used, patients with an abnormal CFR demonstrate increased rates of adverse cardiac 
outcomes (7, 154). 
Another measure of microvascular function is the index of microvascular resistance 
(IMR), which utilizes thermodilution techniques to measure coronary flow, along with the 
pressure gradient across the microvasculature (186). Using Ohm’s Law, the IMR is calculated as 
the product of the distal coronary artery pressure and coronary flow during pharmacological 
hyperemia. An IMR of >25 during intravenous adenosine has been utilized as a clinical cut-off 
for identifying patients with CMD (181). An IMR > 25 is also associated with increased adverse 
cardiac events and mortality in patients with CVD (187, 188). Lastly, several studies have shown 
that concurrently measuring the CFR and IMR can improve the capacity to predict patient 
outcomes (189, 190). The procedures involved in obtaining measures of the CFR and IMR 
during coronary reactivity testing will be described in detail in Section 3.3. 
 
2.6.4.1. Non-Invasive Screening of Vascular Function 
In 1987, Sax and colleagues were one of the first groups to demonstrate that impaired 
vasomotor function may be a systemic condition, not simply specific to the coronary vessels 
(191). Further, the magnitude of coronary vessel dysfunction was correlated with the magnitude 
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of forearm vascular dysfunction (191). Later, in 50 patients with angiographically clear arteries, 
Anderson and colleagues (192) observed modest correlations between coronary endothelial 
function, measured by quantitative angiography during intracoronary acetylcholine infusions, 
and brachial artery FMD. Other studies have measured the CFR from the left anterior descending 
coronary artery (LAD) using transthoracic echocardiography (a strong correlate to invasive 
Doppler wire measures (193)) and observed positive correlations between FMD and the CFR 
during intracoronary dipyridamole infusions (194, 195). However most recently, the iPOWER 
study observed no correlations between FMD and CFR using dipyridamole (196).  
Utilizing RH-PAT as a predictive tool of coronary vascular function has also been 
previously investigated (197–199). Bonnetti and colleagues (197) conducted RH-PAT in patients 
with clear coronary arteries with (n=55) and without (n=39) coronary endothelial dysfunction. It 
was observed that the RHI was an independent predictor of the coronary blood flow response to 
acetylcholine, with an RHI<1.35 yielding highly sensitive results for the detection of coronary 
endothelial dysfunction. Similar findings were observed in women with ischemic heart disease, 
with RH-PAT yielding superior predictive results compared to the Reynolds Risk Score (198), a 
scoring system used to help predict the risk of future cardiovascular events. Contrarily, the 
iPOWER Study demonstrated that in 322 women with non-obstructive coronary artery disease, 
RH-PAT was not correlated to dipyridamole induced CFR (199). These results suggest that RH-
PAT is associated with endothelial-dependent, but not endothelial independent coronary 
microvascular function. 
 
  
  
18 
 
CHAPTER 3 MANUSCRIPT 
 
Flow-mediated dilation and peripheral arterial tonometry are associated with 
pharmaceutical stimulation of the coronary microvasculature 
 
Massimo Nardone, BASca, Steven Miner, MDa,b, Mary McCarthy, NPb, Chris Ardern, PhDa, 
Heather Edgell, PhDa,b 
 
a School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada. 
b Southlake Regional Health Center, Newmarket, Ontario, Canada.  
 
Brief Title: Relationship between peripheral and coronary vascular function 
 
Word Count of Abstract: 250 
Word Count of Manuscript: 5,140 
 
Funding: This research was supported by the Natural Sciences and Engineering Research 
Council of Canada (NSERC), Canadian Foundation for Innovation (CFI), the Ontario Research 
Fund (ORF), the Heart of Gold Cardiac Research Fund, St. Jude Medical, and the Faculty of 
Health York University. M.N. was supported by a Canadian Institute of Health Research (CIHR) 
Fredrick Banting and Charles Best Canadian Graduate Scholarship. 
 
Disclosures: None 
 
 
 
 
 
 
 
To be submitted to Circulation: Cardiovascular Interventions 
  
19 
 
3.1. Abstract 
Background: Reactive hyperemia peripheral arterial tonometry (RH-PAT) and flow-mediated 
dilation (FMD) are common measures of peripheral vascular function. Whether RH-PAT and 
FMD can be used to identify abnormalities in the coronary circulation, particularly in coronary 
microvascular dysfunction (CMD), is unclear. 
 
Objectives: To compare RH-PAT and FMD to coronary microvascular function following 
endothelial independent, endothelial-dependent, and sympathetically-mediated pharmacological 
hyperemia. 
 
Methods: Forty-seven patients with suspected CMD completed peripheral and coronary 
assessments. The reactive hyperemia index (LnRHI) was collected using the EndoPAT2000TM 
device, while a subset of patients (n=28) completed FMD using Duplex ultrasound of the 
brachial artery. Coronary microvascular function was measured using the index of microvascular 
resistance (IMR) and the coronary flow reserve (CFR) during adenosine, acetylcholine, and 
dobutamine infusions. Any abnormality in the IMR and/or CFR during the adenosine and/or 
acetylcholine trials were used to define CMD.  
 
Results: LnRHI and FMD were attenuated in patients with CMD (RH-PAT: No CMD: 0.88 ± 
0.23 vs CMD: 0.63 ± 0.26; FMD: No CMD: 7.8 ± 2.2 vs CMD: 4.8 ± 2.8; P<0.05). RH-PAT was 
correlated with the dobutamine IMR and CFR (ρ= -0.44 and ρ= 0.39; P<0.05). FMD was 
correlated with the adenosine (ρ= -0.48; P<0.05) and acetylcholine IMRs (ρ= -0.66; P<0.05), but 
not the CFRs (P>0.05). RH-PAT and FMD cut-offs of 0.76 and 5.37% had sensitivities of 77% 
and 92%, and specificities of 76% and 69%, respectively, for identifying patients with CMD. 
 
Conclusions: Peripheral endothelial function is attenuated in patients with CMD, while both 
LnRHI and FMD can identify patients with CMD. 
 
Key Words: Coronary microvascular dysfunction, coronary reactivity testing
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Condensed Abstract 
The relationship between reactive hyperemia peripheral arterial tonometry (RH-PAT) or brachial 
artery flow-mediated dilation (FMD), common non-invasive measures of peripheral endothelial 
function, and coronary microvascular function is unclear in CMD. The current study highlights 
that peripheral conduit artery and microvascular endothelial function are attenuated in patients 
with CMD. Further, these results suggest that either RH-PAT or FMD can predict the presence 
of CMD in patients with chest pain and non-obstructive coronary arteries. Thus, these findings 
suggest that both RH-PAT and FMD may be important screening measures for identifying 
patients with CMD.  
 
 
Abbreviations  
CFR  Coronary Flow Reserve 
CMD  Coronary Microvascular Dysfunction 
FMD  Flow-mediated Dilation 
IMR  Index of Microvascular Resistance 
Pa  Proximal Coronary Pressure 
Pd  Distal Coronary Pressure 
RH-PAT Reactive Hyperemia Peripheral Arterial Tonometry 
LnRHI  Natural Logarithm of the Reactive Hyperemia Index 
SRAUC  Shear Rate area under the curve 
Tmn  Mean Transit Time 
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3.2. Introduction 
Coronary microvascular dysfunction (CMD) is emerging as an important contributor to 
chest pain despite non-obstructive coronary arteries (155). Chest pain in patients with CMD is 
often attributed to reduced coronary microvascular vasodilation, and is commonly assessed by 
quantifying the vasomotor responses to either an endothelial-dependent or independent 
pharmacological stimulus (154, 155). Attenuated microvascular dilation is associated with 
increased adverse cardiac events (7, 154, 185), and although multifactorial, is partially facilitated 
by coronary endothelial dysfunction (5, 155).  
Several studies have attempted to assess the association between common non-invasive 
measures of peripheral endothelial function (i.e. reactive hyperemia peripheral arterial tonometry 
(RH-PAT) or brachial artery flow-mediated dilation (FMD) (10, 102)) to the coronary flow 
responses to pharmacological hyperemia, particularly in patients with chest pain and non-
obstructive coronary arteries (195–199). However, several methodological considerations should 
be noted from previous work, making the relationship between invasive coronary measurements 
and non-invasive peripheral vascular function unclear. First, many studies have been limited to 
the assessment of coronary function through echocardiographic measures of coronary flow 
velocity (195, 196, 199). Although the coronary flow velocity may be clinically useful, newer 
techniques can more precisely quantify microvascular function in the coronary circulation (181, 
186). For example, the index of microvascular resistance (IMR), which utilizes thermodilution to 
measure coronary flow with concurrent measures of coronary pressure, has been suggested to be 
a physiologically superior marker of microvascular function, given the reduced hemodynamic 
dependency and increased reproducibility (200). Second, patients with CMD often present with a 
complex interaction of endothelial independent and/or endothelial-dependent coronary 
abnormalities (151), however, most studies tend to only associate peripheral vascular function 
with one specific pharmacological measure of coronary microvascular function (195, 196, 199). 
The assessment of coronary microvascular function using multiple pharmacological stimuli may 
help to determine the mechanisms of CMD and the similarities between coronary and peripheral 
vascular function. Lastly, no previous study has assessed the relationship between peripheral 
vascular function and coronary microvascular function during a simulated sympathetic stimulus, 
important given that cardiac sympathetic activity has been shown to be elevated in patients with 
chest pain and non-obstructive coronary arteries (201). Particularly, dobutamine is a 
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sympathomimetic that augments heart rate, myocardial contractility, myocardial oxygen demand 
and subsequent coronary flow (202, 203). 
The purpose of this study is to compare non-invasive peripheral vascular measures (RH-
PAT and FMD) to invasive measures of coronary resistance and flow following endothelial 
independent (adenosine), endothelial-dependent (acetylcholine), and sympathetically-mediated 
(dobutamine) hyperemia in patients with suspected CMD. Given that the RH-PAT and FMD 
responses are mainly endothelial-dependent (101, 106), we hypothesized that RH-PAT and FMD 
will be associated with coronary resistance and flow during acetylcholine, but not with 
adenosine. Further, the endothelium has been shown to interact with the sympathetic nervous 
system (61), and therefore we hypothesized that RH-PAT and FMD will also be associated with 
coronary resistance and flow during dobutamine. The results of this study will identify non-
invasive clinical measures for screening patients with suspected CMD. 
 
3.3. Methods 
Patient Selection 
Patients referred to the Cardiovascular Integrated Physiology Clinic at Southlake 
Regional Health Centre for the suspicion of coronary microvascular dysfunction (CMD) were 
enrolled in this study. Patients were included in this study if they were experiencing typical or 
atypical chest pain with non-obstructive coronary arteries. Participants were excluded if there 
was evidence of: 1) coronary obstruction, based on a fractional flow reserve < 0.80, or coronary 
stenosis in any coronary vessel > 50%, 2) recent (<1 year) percutaneous coronary intervention or 
coronary artery bypass grafting, 3) exercise induced pulmonary hypertension, 4) heart failure 
with reduced ejection fraction (< 40%), or 5) hypertrophic cardiomyopathy. All procedures were 
approved by the Research Ethics Boards of Southlake Regional Healthcare Centre and York 
University. 
 
Experimental Protocol 
Peripheral Vascular Assessments 
Fifty-seven patients underwent an assessment of peripheral microvascular function using 
reactive hyperemia peripheral arterial tonometry (RH-PAT) using the EndoPAT2000TM device 
(EndoPat, Itamar Medical, Israel). A standard blood pressure cuff was positioned on the right 
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forearm, followed by two applanation tonometry cuffs placed on the index fingers of both hands. 
The applanation tonometry cuffs quantified the pulse amplitude of the finger microvasculature 
during 5 minutes of baseline, 5 minutes of forearm ischemia, and 5 minutes of hyperemia.  
Forearm ischemia was achieved via supra-systolic cuff inflation to either 200 mmHg or 50 
mmHg above systolic blood pressure, while the hyperemic response was initiated via rapid 
deflation of the blood pressure cuff. The pulse amplitude recordings were stored, digitized and 
analyzed by an automated algorithm, which quantified microvascular function as the reactive 
hyperemic index. Due to the non-normal distribution of the reactive hyperemia index (103), the 
natural logarithm of the reactive hyperemia index (LnRHI) was calculated and utilized as the 
primary variable of interest. The EndoPAT device concurrently quantified arterial stiffness by 
measuring the augmentation index (AI) of the arterial waveforms during baseline, and 
subsequently calculated the resting heart rate and the augmentation index at a controlled heart 
rate of 75 bpm (AI@75bpm) (204). 
To quantify conduit artery endothelial function, a subset of participants (n=28) completed 
an assessment of brachial artery flow-mediated dilation (FMD), conducted concurrently with 
RH-PAT. Using a linear array high resolution (9L-RS; 3-10 MHz) ultrasound transducer, the 
brachial artery was imaged in the longitudinal plane proximal to the blood pressure cuff. Duplex 
ultrasound (Vivid i, GE Healthcare Systems, Canada) was obtained for quantification of arterial 
diameter and shear measurements. Duplex ultrasound recordings were obtained for 2.5 minutes 
of baseline, 5 minutes of ischemia, and 2.5 minutes after cuff release.  
Duplex ultrasound files were recorded in video format using a video grabber device 
(AV.io HD, Epiphan Video). Video files were analyzed using an automated software program 
(Cardiovascular Suite, Quipu, Italy). Following calibration, a specific area of interest within the 
B-mode was highlighted, and edge detection and wall tracking software continuously measured 
changes in brachial artery diameter over each cardiac cycle, while shear measurements were 
analyzed using automatic Doppler flow analysis. FMD was calculated as: FMD = [(maximal 
diameter–baseline diameter)/baseline diameter]*100. Shear rate was calculated as: SR = 
4*(velocity/diameter). The shear rate area under the curve (SRAUC) of the first 100 seconds of 
hyperemia was subsequently calculated using the following formula: SRAUC = ∑ {yi (xi+1 – xi) + 
½ (yi+1 – yi)(xi+1 – xi)}, where xi is initial time point, xi+1 is the second following xi, yi is initial 
shear rate, and yi+1 is the shear rate following yi.  
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Coronary Reactivity Testing 
Approximately 5 months following the peripheral vascular assessments, patients 
underwent coronary reactivity testing using the guidewire method, as previously described (181, 
186). In brief, a guide catheter was advanced into the left anterior descending coronary artery, 
followed by the insertion of a 0.014-inch pressure-temperature sensor-tipped guidewire (Abbott 
Vascular). Simultaneously, the guidewire measured coronary pressure at a proximal arterial 
segment (Pa) and distal arterial segment (Pd), respectively. Coronary flow was measured using 
the thermodilution method, where a 3 mL room temperature saline bolus was infused from the 
catheter to the guidewire. The time taken for the saline to arrive at the guidewire (transit time) 
was used to determine coronary flow (205). This was repeated in triplicate and averaged to 
obtain the mean transit time (Tmn), while the inverse of the Tmn was used to estimate absolute 
flow. The fractional flow reserve, calculated as the Pd relative to the Pa, was collected to confirm 
patients did not have significant coronary epicardial stenosis. A fractional flow reserve < 0.80 
was considered hemodynamically significant coronary epicardial stenosis, and if present, patients 
were excluded.  
Measures of coronary pressure (i.e. Pa, Pd) and flow (i.e. Tmn) were collected during 
baseline and pharmacological hyperemia. Three pharmacological stimuli were utilized in the 
following order; intravenous adenosine (140μg/kg/min for at least 1 minute), intracoronary 
acetylcholine (20μg followed by a 100μg slow injection over 90 seconds), and intravenous 
dobutamine (increased by 10μg/kg/min every 3 minutes until a final dose of 40μg/kg/min was 
achieved after 12 minutes), each separated by rest and baseline measures. Measurements were 
obtained at the end of each infusion. Two measures were calculated during infusion to 
diagnostically determine coronary microvascular function; 1) index of microvascular resistance 
(IMR) and 2) coronary flow reserve (CFR). IMR was calculated as the product of the hyperemic 
Pd and the hyperemic Tmn. CFR was calculated as baseline Tmn divided by the hyperemic Tmn 
(206). Patients were considered to have CMD if any of the following criteria were observed: 1) 
adenosine IMR>25, 2) adenosine CFR<2.0, 3) acetylcholine IMR>30, 4) acetylcholine CFR<1.5 
(151, 154, 175, 181).  
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Data and Statistical Analysis 
Normal distribution was assessed using the Spiro-Wilks test of normality. 
Anthropometrics, peripheral and coronary vascular function were compared among patients with 
and without CMD using an independent sample t-test for normally distributed data, and a Mann–
Whitney U test for skewed data. Risk factors and medication use were compared using the Chi-
Square Test. Pearson bivariate correlations or Spearman’s rank order correlations were 
conducted between the non-invasive measures of peripheral vascular function (i.e. LnRHI and 
FMD), and invasive measures of coronary microvascular function (i.e. IMR and CFR). Lastly, 
receiver operating characteristic (ROC) curve analysis was conducted to determine the ROC area 
under the curve (ROCAUC) sensitivities and specificities for LnRHI and FMD to predict a 
diagnosis of CMD. The optimal thresholds for LnRHI and FMD to predict CMD were 
determined by maximizing the sum of the sensitivity and specificity (207). Statistical analyses 
were performed using IBM SPSS Statistics 23 (Armonk, NY). Normally distributed data are 
presented as Mean ± SD and skewed data are presented as Median (25th to 75th percentile); non-
parametric data are presented as Count (%). Significance was defined as P<0.05. 
 
3.4. Results 
Between October 2017 and May 2019, vascular assessments were obtained in 57 patients. 
After excluding patients with an abnormal fractional flow reserve at the time of the coronary 
reactivity testing (n=7), technical difficulties during coronary reactivity testing (n=3) and 
technical difficulties during RH-PAT testing (n=1; though FMD was still obtained in this 
patient), 47 patients were included in this study. Baseline characteristics are shown in Table 1. 
Age, height, weight, BMI, systolic blood pressure, diastolic blood pressure, AI, and AI@75bpm 
were similar between patients with and without CMD (P>0.05; Table 1). Hypertension, 
dyslipidemia, diabetes, smoking status, medication use, time between invasive and non-invasive 
tests, and coronary stenosis were also similar between patients with and without CMD (P>0.05; 
Table 1).  
Of the 47 patients who completed coronary reactivity testing, at least one coronary 
microvascular abnormality was observed in 64% of patients; 23% had an abnormal adenosine 
IMR, 26% had an abnormal adenosine CFR, 38% had an abnormal acetylcholine IMR, and 30% 
had an abnormal acetylcholine CFR. A single coronary abnormality or combinations of two, 
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three, or all four abnormalities were observed in 26%, 28%, 6% and 4% of patients, respectively. 
The adenosine and acetylcholine IMR and CFR responses were lower in patients with CMD 
compared to patients without CMD (P<0.05; Table 2) due to using these IMRs and CFRs as 
diagnostic criteria for CMD. The dobutamine IMR and CFR responses were similar between 
patients with and without CMD (P>0.05; Table 2).  
The LnRHI and FMD measurements were lower in patients with CMD compared to 
patients without CMD (P<0.05; Table 3). Resting brachial artery diameter, SRAUC, and time to 
maximal dilation were similar in patients with and without CMD (P>0.05; Table 3). When 
investigating the correlations between coronary microvascular function and the LnRHI, it was 
observed that the LnRHI did not correlate with the adenosine or acetylcholine IMR and CFR 
(P>0.05; Figure 1A-D). However, the LnRHI was correlated with the dobutamine IMR and CFR 
(P<0.05; Figure 1E and 1F). FMD was correlated with the adenosine IMR (P<0.01; Figure 2A), 
but not with the adenosine CFR (P>0.05; Figure 2B). FMD was also correlated with the 
acetylcholine IMR (P<0.01; Figure 2C), but not with the acetylcholine CFR (P>0.05; Figure 2D). 
Lastly, FMD was not correlated with the dobutamine IMR or CFR (P>0.05; Figure 2E and 2F). 
The LnRHI was not associated with baseline coronary flow, or hyperemic coronary flow 
during the adenosine, acetylcholine, or dobutamine trials (P>0.05; Table 4). Lastly, while FMD 
did not correlate with all baseline coronary flows, or the hyperemic coronary flow during 
dobutamine (P>0.05; Table 4), FMD was correlated with the hyperemic flow response during 
both the adenosine and acetylcholine trials (P<0.05 Table 4).  
The ROCAUC for the LnRHI to predict CMD was 0.78 (95% CI: 0.64 – 0.92; P<0.01). 
Using an LnRHI cut-off of 0.76, the sensitivity and specificity of the LnRHI to predict CMD 
were 77% and 76%, respectively. The ROCAUC for FMD to predict CMD was 0.81 (95% CI: 
0.64 – 0.97; P<0.01). Using an FMD cut-off of 5.37%, the sensitivity and specificity of FMD to 
predict CMD were 92% and 69%, respectively.  
 
3.5. Discussion 
The relationship between LnRHI and FMD to the coronary microvascular responses to 
adenosine, acetylcholine and dobutamine was previously unclear. The main findings of the 
current study are: 1) both LnRHI and FMD are attenuated in patients with CMD, 2) the LnRHI is 
associated with the IMR and CFR responses to intravenous dobutamine, 3) FMD is associated 
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with the IMR response, but not the CFR response to endothelial independent and -dependent 
dilation, and 4) LnRHI and FMD can significantly identify patients with CMD. 
 
Peripheral vascular function is attenuated in CMD  
Patients with chest pain and non-obstructive coronary arteries often present with 
endothelial independent abnormalities, endothelial-dependent abnormalities, or both (151); 
highlighting the importance of measuring the coronary microvascular responses to both types of 
pharmacological stimuli when evaluating patients with suspected CMD. However, prior studies 
failed to consider this complex interaction, limiting the assessment of microvascular function to a 
single pharmacological stimulus (195, 196, 199). Further, the IMR has been suggested to be a 
superior marker of coronary microvascular function compared to the CFR (200), though most 
previous studies have only considered the CFR. When considering both the IMR and the CFR 
during endothelial independent and -dependent pharmacological hyperemia to define patients 
with CMD, our results highlight that RH-PAT and FMD are attenuated in CMD, while both RH-
PAT and FMD can significantly predict the presence of CMD in patients with chest pain and 
non-obstructive coronary arteries. Previous work has shown that in women with chest pain and 
non-obstructive coronary arteries, the ROCAUC for RH-PAT to predict non-obstructive coronary 
artery disease was greater than that observed here (198). However, we attribute the lower area 
under the curve in the current study to: 1) including male patients (representing 34% of the 
sample), given that sex differences have been previously observed in both peripheral and 
coronary microvascular function (103, 206), and 2) not including coronary epicardial responses 
to acetylcholine as a diagnostic criteria for CMD, given the a priori objective of investigating the 
relationship between RH-PAT and FMD to coronary microvascular function. Nonetheless, our 
findings support the concept that peripheral endothelial function can provide important 
information about overall vascular function in the coronary circulation.  
 
Adenosine 
 Attenuated endothelial independent coronary vasodilation is associated with increased 
adverse cardiac events in patients with suspected CMD (7, 154), highlighting the clinical 
relevance of investigating the relationship between endothelial independent coronary 
vasodilation and peripheral vascular function (195, 196, 199). In the current study, no association 
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was observed between LnRHI and the IMR or CFR during intravenous adenosine, supporting 
prior work that observed no correlation between RH-PAT and the coronary flow velocity reserve 
during intravenous dipyridamole in women with chest pain and non-obstructive coronary arteries 
(199).  
Studies associating FMD and endothelial independent coronary vasodilation have 
observed opposing results (195, 196). Specifically, the coronary flow velocity reserve during 
intravenous dipyridamole was associated with brachial artery FMD in men and women with 
chest pain and non-obstructive coronary disease (195), though more recent findings in women 
with non-obstructive coronary artery disease observed no association using the same measures 
(196). Considering that coronary function in previous work was measured indirectly using 
transthoracic echocardiography (195, 196), the results of the current study are superior to 
previous studies since thermodilution and measures of coronary pressure were obtained to more 
accurately assess the coronary microvasculature. In the current study, the FMD response was 
associated with hyperemic coronary flow during intravenous adenosine, yet it was not associated 
with coronary flow at baseline. Considering that the CFR is calculated as the ratio of hyperemic 
coronary flow to baseline coronary flow, FMD was also not associated with the CFR in the 
current study. However, we did find a significant correlation between FMD and IMR during 
intravenous adenosine, and given the proposed superiority of the IMR as a marker of coronary 
microvascular function (200), our results imply that brachial artery FMD is associated with 
endothelial independent coronary vasodilation in men and women with suspected CMD. In 
support of these findings, Al-Badri and colleagues observed that changes in femoral vascular 
resistance to acetylcholine was also associated with the change in coronary vascular resistance to 
adenosine (208).  
 
Acetylcholine 
Acetylcholine, an endothelial-dependent pharmacological stimulant, activates muscarinic 
receptors leading to the synthesis of nitric oxide and subsequent vasodilation, however, in 
dysfunctional coronary vasculature, acetylcholine can directly interact with vascular smooth 
muscle cells and cause paradoxical vasoconstriction (209). The nitric oxide dependency of RH-
PAT and acetylcholine-mediated vasomotion (106, 210) suggests that these measures should 
assess vascular function via similar pathways. However, contrary to previous studies (197, 198), 
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the current study did not observe an association between LnRHI and the IMR, CFR, or baseline 
and hyperemic flow responses to intracoronary acetylcholine. Discrepancies between studies 
may be due to the location of the blood pressure cuff that elicited ischemia during the RH-PAT 
assessment. Prior studies that observed an association between RH-PAT and endothelial-
dependent coronary function utilized upper arm ischemia (197, 198), while the current study 
utilized forearm ischemia to enable concurrent measures of brachial artery FMD. However, 
forearm occlusion tends to produce a smaller RH-PAT response compared to upper arm 
occlusion (211). Considering that upper arm ischemia elicits an RH-PAT response that is <50% 
nitric oxide mediated, it is possible that forearm ischemia may reduce the nitric oxide 
contribution, thereby reducing its association with an endothelial-dependent stimulus in the 
coronary vasculature.  
FMD is well established to be highly endothelial-dependent, given the large contribution 
of nitric oxide to the vasodilatory response (101). Although several studies have shown that 
brachial artery FMD is associated with coronary epicardial vasomotion during endothelial-
dependent pharmaceutical infusions (184, 192, 212), no study to date has assessed the 
relationship between FMD and endothelial-dependent cardiac microvascular vasodilation.  In the 
current study, FMD was associated with the IMR and the hyperemic flow response to 
intracoronary acetylcholine, but not with baseline coronary flow or CFR, supporting previous 
studies associating FMD with coronary epicardial vasomotion during intracoronary acetylcholine 
(192, 212). Similar to the coronary microvascular responses to adenosine described above, FMD 
was not correlated with the acetylcholine CFR likely due to variability within the baseline flow. 
Our results suggest that FMD, but not RH-PAT, is associated with coronary microvascular 
function during endothelial-dependent vasodilation. 
 
Dobutamine 
Endothelial function can influence the vasomotor responses to sympathetic stimulation in 
the coronary circulation. For instance, sympathetic activation via the cold pressor test caused 
epicardial dilation in young healthy humans (213), yet caused epicardial vasoconstriction in 
patients with coronary endothelial dysfunction (214). Further, intravenous dobutamine also 
causes epicardial dilation in patients with normal coronary arteries, a response that is attenuated 
in patients with mildly atherosclerotic arteries and abolished in patients with significant 
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epicardial stenosis (215). Facilitated by β adrenergic receptor activation, dobutamine is a 
sympathomimetic that augments coronary flow due to the increase in myocardial oxygen demand 
produced by the enhanced cardiac inotropy and chronotropy (202) and the activation of 
vasodilatory β2 adrenergic receptors (202). In the current study, RH-PAT was associated with the 
IMR and CFR response to dobutamine, implying that peripheral microvascular endothelial 
function can provide insight into the coronary vasodilatory responses to sympathetic stimulation 
by the sympathetic nervous system. Indeed, RH-PAT has been shown to be inversely associated 
with muscle sympathetic nerve activity in healthy participants (216).  
FMD was not associated with coronary microvascular function during dobutamine 
infusions. Conduit arteries receive less sympathetic innervation and are less susceptible to 
sympathetic neurovascular transduction compared to the microvasculature (29, 34), implying that 
conduit artery endothelial function may be less influenced by sympathetic activation. Although 
prior studies have shown that sympathetic activity can attenuate brachial artery FMD (217–219), 
this is likely secondary to sympathetic activity altering conduit artery shear patterns (218, 220). 
Collectively, these results suggest that peripheral microvascular, but not conduit artery 
endothelial function, can provide insight into coronary microvascular function during 
sympathetic stimulation, likely due to microvascular endothelial function being under greater 
influences of sympathetic activity compared to conduit arteries. 
 
Limitations 
First, the time between the non-invasive vascular assessment and coronary reactivity 
testing was ~150 days due to clinical scheduling. Although medication regime was unaltered 
during this time, we cannot rule out that vascular function could have been altered by disease 
progression or lifestyle changes. Second, we recognize that no study to date has confirmed the 
acetylcholine IMR diagnostic cut-off of >30, and therefore its clinical relevance has yet to be 
confirmed. Third, this study did not assess peripheral endothelial independent dilation via 
nitroglycerin-mediated dilation. By adding this third non-invasive measurement we could have 
determined the endothelial independent relationship between peripheral and coronary vascular 
function.  
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Conclusions 
LnRHI and FMD are lower in patients with CMD compared to patients without CMD, 
and either LnRHI or FMD can identify the presence of CMD in patients with chest pain and non-
obstructive coronary arteries. Particularly, the LnRHI is associated with the IMR and CFR 
responses to intravenous dobutamine, while FMD is associated with the IMR responses to 
intravenous adenosine and intracoronary acetylcholine. These findings suggest that both RH-
PAT and FMD can be used to screen patients with suspected CMD.  
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3.6. Clinical Perspectives 
Clinical Competencies: 
RH-PAT and FMD are attenuated in patients with CMD, and can significantly identify patients 
with CMD. These results suggest that non-invasively measuring peripheral vascular function can 
be an important clinical tool to help screen patients with chest pain and non-obstructive coronary 
arteries for the presence of CMD.  
 
Translational Outlook: 
Utilizing RH-PAT or FMD to screen patients with chest pain and non-obstructive coronary 
arteries and suspected CMD may help to identify patients who may require further testing. This 
may help patients reach a diagnosis faster, leading to improved quality of life and reduced 
medical healthcare costs. Additional studies should focus on how the combination of non-
invasive vascular assessments and other traditional clinical variables can be concurrently 
integrated to help improve the capability to identify patients with CMD.   
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Figure Legends 
 
Figure 1: RH-PAT and Coronary Microvascular Function 
Correlations between the LnRHI and the IMRs (left panels) and the CFRs (right panels) to 
adenosine (A and B; n=46), acetylcholine (C and D; n=46), and dobutamine (E and F; n=28). 
CFR: Coronary Flow Reserve, LnRHI: Natural Logarithm of the Reactive Hyperemia Index, 
IMR: Index of Microvascular Resistance, ρ: Spearman’s Rho. 
 
 
Figure 2: FMD and Coronary Microvascular Function  
Correlations between brachial artery FMD and the IMRs (left panels) and the CFRs (right 
panels) to adenosine (A and B; n=28), acetylcholine (C and D; n=28), and dobutamine (E and F; 
n=17). CFR: Coronary Flow Reserve, FMD: Flow-Mediated Dilation, IMR: Index of 
Microvascular Resistance, ρ: Spearman’s Rho. 
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Table 1: Anthropometrics, hemodynamics, traditional cardiovascular risk factors, and 
medication use in patients with or without coronary microvascular dysfunction (CMD).  
 
       
Variable    All Patients  No CMD  CMD  
n    47   17   30  
Sex (male)   16 (34)  5 (29)   11 (37) 
Age (years)   60 ± 13  56 ± 12  62 ± 14  
Weight (kg)   78.6 ± 16.2  77.4 ± 20.0  79.2 ± 14.0 
Height (m)   1.67 ± 0.09  1.67 ± 0.10  1.67 ± 0.09 
BMI (kg/m2)   28.0 ± 4.7  27.7 ± 6.0  28.2 ± 3.8 
SBP (mmHg)   125 ± 15  122 ± 18  126 ± 14 
DBP (mmHg)   76 ± 10  76 ± 9   76 ± 10 
AI      23.3 ± 21.4  24.4 ± 20.9  22.7 ± 22.1 
AI@75bpm   16.6 ± 20.3  16.4 ± 18.4  16.7 ± 21.7 
Risk Factors 
 Hypertension  21 (45)  6 (35)   15 (50) 
 Dyslipidemia  22 (47)  7 (41)   15 (50) 
 Diabetes   9 (19)   1 (6)   8 (27)   
 Smoker   17 (36)  4 (24)   13 (43) 
Medication use 
 BB    18 (38)  5 (29)    13 (43) 
 ACE or ARB  21 (45)  6 (35)   15 (50) 
 Statins   28 (60)  9 (53)   19 (63) 
 CCB   15 (32)  6 (35)   9 (30) 
 Aspirin   29 (62)  12 (71)  17 (57) 
Time between tests (days) 151 ± 53  153 ± 55  150 ± 53 
Stenosis of LAD (%)  25 (0 – 30)  0 (0 – 30)  25 (0 – 25) 
ACE: Angiotensin Converting Enzyme Inhibitor, AI: Augmentation Index, AI@75bpm: 
Augmentation Index at 75bpm, ARB: Angiotensin Receptor Blocker, BB: Beta-Blocker,  
BMI: Body Mass Index, CCB: Calcium Channel Blocker, DBP: Diastolic Blood Pressure, LAD: 
Left Anterior Descending Coronary Artery, SBP: Systolic Blood Pressure. Parametric data 
presented as Mean ± SD. Skewed parametric data presented as Median (25th – 75th percentile). 
Non-parametric data presented as Count (%).  
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Table 2: The index of microvascular resistance (IMR) and coronary flow reserve (CFR) 
responses to adenosine, acetylcholine, and dobutamine in patients with and without coronary 
microvascular dysfunction (CMD). 
 
       
Variable    All Patients  No CMD  CMD 
Adenosine 
  n    47   17   30 
  IMR   17.7 (14.3 – 24.8) 14.3 (11.5 – 18.9) 19.8 (16.3 – 29.1)* 
  CFR   3.0 (1.9 – 4.1)  3.6 (3.0 – 4.6)  2.4 (1.8 – 3.5)* 
Acetylcholine 
  n    47   17   30 
  IMR   26.2 (18.8 – 41.4) 18.5 (16.5 – 22.7) 31.9 (25.9 – 46.8)* 
  CFR   1.8 (1.3 – 2.6)  2.6 (2.0 – 3.4)  1.5 (1.1 – 2.0)* 
Dobutamine 
  n    28   11   17 
  IMR   24.6 (18.0 – 33.6) 21.8 (17.3 – 25.9) 27.0 (19.4 – 45.0) 
  CFR   2.0 (1.6 – 2.7)  2.2 (2.1 – 3.1)  1.8 (1.3 – 2.4) 
Skewed parametric data presented as Median (25th – 75th percentile). * indicates a significant 
difference between patients with and without CMD (P<0.05). 
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Table 3: Peripheral vascular function, obtained during reactive hyperemia peripheral arterial 
tonometry (RH-PAT) and brachial artery flow-mediated dilation (FMD) assessments in patients 
with and without coronary microvascular dysfunction (CMD).  
 
       
Variable    All Patients  No CMD  CMD 
RH-PAT 
 n     46   17   29 
 LnRHI   0.72 ± 0.27  0.88 ± 0.23  0.63 ± 0.26* 
FMD 
 n     28   12   16 
 Resting Diameter (mm) 3.75 ± 0.68  3.89 ± 0.75  3.64 ± 0.60 
 FMD (%)   6.2 ± 2.9  7.8 ± 2.2  4.8 ± 2.8* 
 FMD (mm)   0.23 ± 0.12  0.30 ± 0.11  0.17 ± 0.09* 
 SRAUC x 10
-3 (sec-1) 48.2 ± 18.6  43.1 ± 15.5  51.6 ± 19.9 
 Time to Max Dilation (s) 44 (35 – 70)   42 (34 – 67)  47 (37 – 70) 
LnRHI: Natural logarithm of Reactive Hyperemia Index, SRAUC: Shear Rate Area under the 
Curve. Normally distributed parametric data presented as Mean ± SD. Skewed parametric data 
presented as Median (25th – 75th percentile). * indicates a significant difference between patients 
with and without CMD (P<0.05). 
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Table 4: Correlations coefficients when comparing the natural logarithm of the reactive 
hyperemia index (LnRHI) and brachial artery flow-mediated dilation (FMD) with baseline and 
hyperemic coronary flow responses to adenosine, acetylcholine, and dobutamine.  
 
  
    Baseline Flow (1/Tmn)   Hyperemic Flow (1/Tmn) 
Adenosine 
  LnRHI    0.06     0.24 
  FMD    0.09     0.51* 
Acetylcholine 
  LnRHI    0.05     -0.01 
  FMD    0.15     0.63* 
Dobutamine 
  LnRHI    -0.09     0.30 
  FMD    0.17     0.35 
Spearman’s rho were calculated due to non-normal distribution of invasive vascular measures. * 
indicates significant association (P<0.05). 
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CHAPTER 4 EXTENDED DISCUSSION 
 
RH-PAT and Sympathetic Activity: Role of  Adrenergic Receptors 
In the current thesis, dobutamine, a β adrenergic receptor agonist, was utilized to assess 
coronary function during a sympathetic stimulus, and was compared with endothelial function in 
the peripheral circulation. We observed that peripheral microvascular, but not conduit artery 
endothelial function was associated with coronary microvascular function during intravenous 
dobutamine.  Endothelial function and sympathetic activity likely have a greater interaction 
effect within the microcirculation due to greater sympathetic innervation and greater 
susceptibility to sympathetic neurovascular transduction, as previously mentioned (29, 34). 
However, despite the inverse association between RH-PAT and muscle sympathetic nerve 
activity (216), phenylephrine, an α1 adrenergic agonist, does not attenuate the hyperemic finger 
pulse amplitude during RH-PAT (106), suggesting a potential role of β adrenergic receptors in 
the RH-PAT response. Particularly, β2 adrenergic receptors are highly prevalent within the 
microcirculation (221), and possess a direct vasodilatory effect in both the coronary (202) and 
forearm circulation (222). Further, the vasodilatory responses to β adrenergic receptor mediated 
dilation were attenuated by NO blockade in both the coronary and peripheral microvascular 
circulation (221, 222). Collectively, these studies suggest that β adrenergic receptors may play a 
role in the RH-PAT response, though future studies are needed to confirm this hypothesis. 
 
Arterial Stiffness and Coronary Microvascular Function 
Increased arterial stiffness can augment blood pressure and left ventricular afterload, due 
to the increases in both retrograde blood flow velocity and amplitude (20, 28). To investigate if 
arterial stiffness can impact coronary microvascular function, the augmentation index at a 
controlled heart rate of 75 bpm (AI@75bpm) was compared with coronary microvascular 
function (Appendix A: Figure 1A-F). Contrary to previous reports (171, 174), the AI@75bpm 
was not associated with coronary microvascular function during adenosine, acetylcholine, or 
dobutamine mediated pharmacological hyperemia. Several studies observed that both the aortic 
augmentation index (174) and the carotid artery augmentation index (171) were associated with 
the CFR response to intravenous adenosine in patients with CMD, implying that arterial stiffness 
in the large, mainly elastic arteries, is associated with coronary function. However, in the current 
 41 
 
study augmentation index was obtained from the finger microvasculature using the EndoPAT 
device, suggesting that arterial stiffness in the microvasculature may differ from those obtained 
in larger arteries, though no study has directly compared both measures. Interestingly, the 
AI@75bpm was positively associated with absolute baseline coronary flow (Appendix A; Figure 
2A), implying that the myocardial oxygen demand at baseline was elevated in patients with 
increased arterial stiffness. In support of this, the baseline rate pressure product (RPP; the 
product of baseline heart rate and baseline systolic blood pressure that has previously been 
utilized as an indirect marker of myocardial oxygen consumption (223)) was also associated with 
the AI@75bpm (Appendix A: Figure 2B). Therefore, these data indicate that arterial stiffness is 
associated with both myocardial oxygen consumption and resting coronary flow, however, 
arterial stiffness obtained from the finger microvasculature is not associated with coronary 
microvascular function.    
 
RH-PAT and Acute Exercise in Clinical Practice 
 Standard guidelines for conducting RH-PAT using the EndoPAT device have not been 
established. Although exercise has been shown to attenuate brachial artery endothelial function 
(224), the effect of exercise on RH-PAT within clinical setting has not been assessed, important 
considering that exercise stress testing is commonly conducted in clinical practice. Using a cross 
sectional design, we determined that exercise stress testing prior to EndoPAT testing 
significantly attenuated peripheral microvascular function in chest pain patients with and without 
CMD (Appendix B). To avoid the potential confounding effect of exercise on peripheral 
microvascular function, patients who exercised prior to EndoPAT testing were excluded from the 
current thesis paper. Additionally, these results suggest that clinicians who adopt RH-PAT 
testing in clinical settings should avoid exercise stress testing prior to assessing peripheral 
microvascular function.  
 
Clinical Implications 
Identifying patients with suspected CMD can be clinically challenging. Currently, 
exercise stress testing with 12 lead electrocardiography is commonly used in clinical practice to 
assess for myocardial ischemia, and a full examination of the coronary arteries is necessary to 
distinguish CSX from obstructive artery disease. Patients with an abnormal exercise stress test 
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and non-obstructive coronary arteries are diagnosed with CSX, as previously described. 
However a diagnosis of CSX does not necessarily imply that patients also have CMD, given that 
several studies have shown that ST segment depression observed during exercise stress testing 
does not adequately identify patients with CMD (151, 225). This may be due to the diffuse 
pattern of ischemia observed in CMD, as patients with CMD likely have myocardial ischemia in 
small, localized regions of the myocardium that likely do not generate detectable changes within 
the ST segment during exercise (226, 227). Additionally, dobutamine stress echocardiography 
has also been suggested as another potential screening measure for CMD (228, 229), however 
these tests are more technically and clinically challenging for large scale implementation. 
Therefore, current clinical tests do not adequately screen patients with chest pain and normal 
coronary arteries, suggesting that new non-invasive measures should be considered. The results 
of the current thesis, along with prior work (197, 198) collectively suggest that the assessment of 
endothelial function using the peripheral vasculature may help provide clinicians with a novel 
screening measure to estimate vascular function in the coronary microcirculation.  
 
Future Studies  
 Despite the current thesis and other work showing moderate sensitivities of RH-PAT and 
FMD for identifying patients with CMD (197, 198), additional work is still needed to answer 
important knowledge gaps within the current literature. First, sex differences are highly prevalent 
in the diagnosis of CMD (151), and sex differences exist in both the coronary and peripheral 
vasculature (114, 206). Therefore, further studies should investigate if sex differences exist in the 
capacity for RH-PAT and FMD to predict a CMD diagnosis in addition to determining optimal 
sex specific thresholds for diagnosis using these non-invasive peripheral vascular measures. 
Additionally, future studies should investigate the synergistic effect of abnormal peripheral 
vascular function and other traditional cardiovascular risk factors, to determine if a combination 
of variables can improve the predictive capacity of RHPAT and FMD within clinical settings.  
 
Limitations 
Important limitations to the current thesis have been highlighted in the manuscript above. 
However, the effects of intravenous pharmacological infusions on the sympathetic nervous 
system should also be addressed. In particular, although dobutamine acts as a sympathomimetic, 
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dobutamine has been shown to decrease muscle sympathetic nerve activity (230), and cardiac 
norepinephrine spillover (231). Therefore, the reduced cardiac sympathetic nerve activity could 
enhance the vasodilatory response in the coronary vasculature. Indeed, the α1 adrenergic receptor 
blocker phentolamine significantly improved coronary epicardial dilation during intravenous 
dobutamine in patients with severe coronary stenosis (215) highlighting that the α1 adrenergic 
receptors influence the coronary vasomotor responses to dobutamine. Additionally, adenosine 
can increase muscle sympathetic nerve activity (232, 233) and cardiac sympathetic activity (234, 
235), thereby potentially attenuating the endothelial independent dilatory response of adenosine. 
Therefore, modulations in cardiac sympathetic activity by either dobutamine or adenosine may 
confound the coronary vasodilatory responses, possibly reducing the association between 
peripheral and coronary microvascular function.  
 
Conclusions 
In conclusion, this thesis demonstrated that peripheral endothelial function is attenuated 
in CMD, while both the RH-PAT and FMD may provide important clinician information for 
identifying patients with suspected CMD. Particularly, brachial artery FMD is associated with 
coronary microvascular function during intravenous adenosine and intracoronary acetylcholine, 
while RH-PAT is associated with coronary microvascular function during intravenous 
dobutamine.   
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APPENDIX A: ARTERIAL STIFFNESS AND CORONARY FUNCTION 
 
 
 
Figure 1: Correlations between the augmentation index at a controlled heart rate of 75bpm 
(AI@75bpm) and the index of microvascular resistance (IMR; left panels) and the coronary flow 
reserve (CFR; right panels) to adenosine (A and B; n=46), acetylcholine (C and D; n=46), and 
dobutamine (E and F; n=28). ρ: Spearman’s Rho. 
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Figure 2: Correlations between the augmentation index at a controlled heart rate of 75bpm 
(AI@75bpm) and resting coronary flow (A; n=46) and the resting rate pressure product (RPP; B; 
n=46). ρ: Spearman’s Rho. 
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Abstract 
The effect of exercise on the microvasculature of patients with suspected coronary microvascular 
disease (CMD), assessed by reactive hyperemia peripheral arterial tonometry (RHPAT), is 
unknown. Further, RHPAT assessments may be particularly useful for screening patients with 
suspected CMD, though exercise stress testing is also commonly conducted in clinical practice.  
Therefore, the present study aimed to determine if standard clinical exercise stress testing (Bruce 
treadmill protocol; GXT) affected peripheral microvascular function, as determined by reactive 
hyperemia index (RHI and LnRHI), in patients with suspected CMD. Patients (n=68) were 
grouped based on whether the GXT was performed; 1) prior to (exercisers; n=26), or 2) after the 
vascular assessment (non-exercisers; n=42). Patients with abnormal coronary flow or resistance 
responses to adenosine- and/or acetylcholine-induced hyperemia were confirmed to have CMD 
(n=41). LnRHI was lower in patients with CMD compared to patients with normal coronary 
arteries, while LnRHI was also lower in exercisers compared to non-exercisers (LnRHI: CMD 
Non-Exercisers: 0.65±0.23; CMD Exercisers: 0.50±0.23; No CMD Non-Exercisers; 0.85±0.23; 
No CMD Exercisers: 0.65±0.25; Condition and Exercise Main Effects: Both P<0.01). In all 
exercisers, there was a significant association (r=0.54; P<0.01) comparing the time between the 
GXT and RHPAT tests and LnRHI, and the correlations did not differ between conditions 
(CMD: r=0.57 vs No CMD: r=0.55; P=0.95). Our results demonstrate that patients with CMD 
display impaired microvascular function, and suggests that exercise impairs microvascular 
function in all patients. We recommend that exercise should be avoided prior to RHPAT 
determination in clinical settings. 
 
Key words: peripheral arterial tonometry, EndoPAT, acute exercise, augmentation index. 
 
Summary  
Reactive hyperemia peripheral arterial tonometry (RHPAT) is increasingly recognized as a 
potential screening measure for patients with suspected coronary microvascular dysfunction 
(CMD), though the effects of exercise are unknown. The current study highlights that patients 
with confirmed CMD have impaired peripheral microvascular function, and that exercise stress 
testing attenuates microvascular function in all patients with suspected CMD. We recommend 
that exercise should be avoided prior to RHPAT determination in clinical settings.  
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Introduction 
Coronary microvascular dysfunction (CMD), defined by abnormal coronary 
microvascular vasomotion, is increasingly recognized as an important contributor to adverse 
cardiac outcomes (6, 7, 236). Although unclear and multifactorial, endothelial dysfunction likely 
plays an important role in facilitating the observed abnormalities in CMD (155, 237, 238). Given 
that endothelial dysfunction is thought to systemically affect the vasculature (191, 195), 
measuring endothelial function from the peripheral circulation may be an effective time and cost-
efficient analysis for identifying patients with CMD. In particular, reactive hyperemia peripheral 
arterial tonometry (RHPAT), as measured by EndoPAT, is emerging as a novel measure of 
microvascular function, and is obtained by quantifying the hyperemic response within the finger 
microvasculature following brief ischemia (239, 240). Poor peripheral microvascular function, 
using RHPAT,  has been shown to identify patients with both non-obstructive coronary artery 
disease(198), and early coronary atherosclerosis (197), supporting it’s utility within clinical 
settings.  
The impact of acute exercise on RHPAT in patients with CMD is currently unknown, 
however, conclusions from studies conducted in the conduit arteries of healthy participants have 
highlighted that acute exercise briefly attenuates endothelial function (dependent on the duration, 
intensity, and type of exercise, as reviewed by Dawson et al.(224)). It is currently unclear 
whether patients with cardiovascular disease, in particular CMD, experience an exaggerated 
reduction of endothelial function following exercise, given that baseline impairments in 
endothelial function are thought to impair the post-exercise vascular response (224). Therefore, 
the present study aimed to determine; 1) if patients with confirmed CMD exhibit impaired 
peripheral microvascular function, and 2) if standard clinical exercise stress testing, commonly 
conducted within clinical practice, acutely affects peripheral microvascular function in patients 
with suspected CMD. We hypothesized that 1) patients with CMD will have significantly lower 
peripheral microvascular function, 2) exercise will impair peripheral microvascular function in 
all patients with a greater effect in those with confirmed CMD.  
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Methods  
Patient selection  
Sixty eight patients with suspected coronary microvascular disease (CMD) who attended 
the Cardiovascular Integrative Physiology Clinic at Southlake Regional Health Centre were 
recruited for this study. Subjects were included in this study if they underwent reactive 
hyperemia peripheral arterial tonometry (RHPAT) assessments and coronary reactivity testing, to 
functionally assess peripheral and coronary microvascular function, respectively. Coronary 
reactivity testing was conducted if participants were experiencing typical or atypical chest pain, 
and had angiographic evidence of normal coronary arteries. Participants did not undergo 
coronary reactivity testing if the cardiologist determined that there was evidence of coronary 
obstruction based on prior angiography, or recent treatment (<1 years) of a percutaneous 
coronary intervention. All procedures were approved by the Research Ethics Boards of 
Southlake Regional Healthcare Centre and York University. 
 
Experimental Protocol 
In a cross-sectional design, patients were grouped based on whether an exercise stress test 
was performed 1) prior to, or 2) following the vascular assessment. The exercise assessment 
consisted of a symptoms-limited maximal exercise stress test (GXT) using the Bruce protocol 
with concurrent 12-lead electrocardiography. The Duke Treadmill Score (DTS) was 
subsequently calculated, using the formula: DTS= Exercise time – (5 x Max exercise ST) – (4 x 
Angina Index), as previously ascribed for risk classification (241). Maximum exercise ST 
depression was the maximal depression present during exercise, where a maximal ST segment 
depression of ≥0.1 mV was considered relevant myocardial ischemia. The angina index was 
ranked 0-2; 0 defined as no chest pain, 1 defined as non-limiting chest pain, and 2 defined as 
limiting chest pain. The time duration between the GXT and the vascular assessment was 
documented.  
Prior to the vascular assessment, blood pressure was manually obtained, and height and 
weight were recorded. Non-invasive assessment of peripheral microvascular function was 
conducted using reactive hyperemia peripheral arterial tonometry (RHPAT) (EndoPat, Itamar 
Medical, Israel). Briefly, an applanation tonometry cuff was placed on the index finger of both 
hands. A standard blood pressure cuff was then positioned on the right arm, immediately distal to 
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the elbow joint. Five minutes of baseline recordings preceded 5 minutes of forearm ischemia, 
which involved supra-systolic cuff inflation to either 200 mmHg or 50 mmHg above systolic 
blood pressure. Subsequently, the blood pressure cuff was quickly deflated to allow reperfusion 
of the distal limb for an additional 5 minutes. The pulse amplitude recordings were stored, 
digitized and analyzed by an automated algorithm, which quantified the hyperemic response as 
the reactive hyperemic index (RHI) and the natural logarithm of the RHI (LnRHI) (to account for 
the non-normal distribution of RHI) (102). The finger-based peripheral artery tonometry device 
concurrently quantified arterial stiffness by measuring the augmentation index (AI) of the arterial 
waveforms in the right finger during baseline, averaged over more than 100 cardiac cycles. 
Further, due to the temporal relationship between heart rate and augmentation index (204), AI 
was also calculated at a controlled heart rate of 75 beats per minute (AI@75bpm). 
Approximately 5 months later, patients underwent coronary reactivity testing using the 
Doppler guidewire method, as previously described (200, 206). In brief, a guiding catheter was 
advanced into the left anterior descending coronary artery (LAD), followed by the insertion of a 
0.014-in pressure-temperature sensor-tipped Doppler guidewire as distal as possible into the 
coronary vessel. Simultaneously, the catheter and the Doppler guidewire measured coronary 
pressure at a proximal arterial segment (Pa) and distal arterial segment (Pd), respectively. 
Coronary blood flow was measured using the thermodilation method, where a 3 mL room 
temperature saline bolus was infused from the catheter to the Doppler guidewire. The time taken 
for the saline to arrive at the Doppler guidewire (transit time) was used to determine coronary 
flow (205). This was repeated in triplicate and averaged to obtain the mean transit time (Tmn). 
The fractional flow reserve (FFR) was collected to confirm patients did not have significant 
coronary epicardial stenosis. An FFR<0.80 was considered to be hemodynamically significant 
coronary epicardial stenosis, and if present, patients were excluded.  
Measures of coronary pressure (i.e. Pa, Pd) and flow (i.e. Tmn) were collected during 
baseline and pharmacological-induced hyperemia. Two pharmacological stimuli were infused 
into the LAD in the following order; intravenous adenosine (140mcg/kg/min), and intracoronary 
acetylcholine (20μg followed by a 100μg slow injection over 90 seconds). Prior to infusion of 
subsequent pharmacological stimuli, baseline measures of pressure and flow were again 
collected to ensure hemodynamics returned to baseline, including resolution of any chest pain. 
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Two measures were calculated during infusion to diagnostically determine coronary 
microvascular function; 1) coronary flow reserve (CFR), and 2) index of microvascular 
resistance (IMR). CFR was calculated as baseline Tmn divided by the hyperemic Tmn. IMR was 
calculated as the product of the hyperemic Pd and the hyperemic Tmn (206). Patients were 
considered to have CMD if any of the following criteria were observed (151, 175, 181): 1) 
Adenosine IMR>25, 2) Adenosine CFR<2.0, 3) Acetylcholine IMR>30, 4) Acetylcholine 
CFR<1.5.  
 
Data and Statistical Analysis 
 Anthropometric data, GXT data, coronary reactivity testing data, and RHPAT data were 
compared using a two by two factorial ANOVA. Levene’s test of equality of variances was 
conducted prior to all ANOVA analyses. If a significant interaction was observed from the 
ANOVA, post hoc testing was conducted with the Bonferroni adjustment. The time between the 
GXT and the vascular assessment was compared between groups using an independent samples 
t-test. Medication regimen was grouped based on if subjects were taking; 1) any anti-
hypertensive medications (i.e. one or more of the following: beta-adrenergic antagonist, 
angiotensin converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), diuretics, 
or a calcium channel blocker), and 2) any anti-cholesterol medications (i.e. one or more of the 
following: statin or cholesterol absorption inhibitors). Medication usages were compared 
between groups using Chi squared testing. Further, use of either medication (i.e. anti-
hypertensive and anti-cholesterol medications) and fasted state were utilized as covariates for 
ANCOVA analysis.  
Lastly, to investigate the effect of time between the GXT and the vascular assessment, 
Pearson correlations between the LnRHI and the time between tests in exercisers with or without 
CMD were conducted. The correlations between the LnRHI and the time between tests in both 
conditions were calculated and compared using a Fisher r-z transformation, calculated using an 
online calculator (VassarStats). All other statistical analyses were performed using IBM SPSS 
Statistics 23 (Armonk, NY). Parametric data is presented as Mean ± SD, while non-parametric 
data is presented as Count (%). Significance was defined as P<0.05. 
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Results 
 Between May 2017 and April 2019, 134 patients with suspected coronary microvascular 
dysfunction (CMD) attended the Cardiovascular Integrated Physiology Clinic at Southlake 
Regional Healthcare Centre for reactive hyperemia peripheral arterial tonometry (RHPAT) 
assessments. After exclusion of patients who experienced technical errors during RHPAT 
assessments (n=9), patients who did not receive a referral for coronary reactivity testing (n=20), 
patients who did not complete coronary reactivity testing (n=31), and patients who had 
hemodynamically significant coronary epicardial stenosis (n=6), the sample consisted of 27 
patients with normal coronary microvascular function and 41 patients with CMD (Figure 1).  
In patients with CMD, 26 patients did not exercise prior to assessment, and 15 patients 
exercised prior to assessment. In those without CMD, 16 patients did not exercise prior to 
assessment, and 11 patients exercised prior to assessment. There were no differences in 
anthropometrics, resting blood pressure, or fasted state between all groups (P>0.05; Table 1). 
Resting heart rate was elevated in exercisers compared to non-exercisers (P=0.02; Table 1). Prior 
to coronary reactivity testing, a greater proportion of patients with confirmed CMD were taking 
anti-hypertensive and anti-cholesterol medications compared to patients without CMD (P<0.05; 
Table 1). Patients with confirmed CMD had greater index of microvascular resistance (IMR) 
responses to both adenosine and acetylcholine (P<0.001; Table 2), and lower coronary flow 
reserve (CFR) responses to both adenosine and acetylcholine (P<0.05; Table 2) compared to 
patients without CMD. There was no difference in coronary microvascular function between 
non-exercisers and exercisers in both conditions (P>0.05; Table 2). 
Five patients in both non-exerciser groups did not complete the graded exercise stress test 
at any time as a part of their normal clinical care (GXT; Table 3). In patients who were able to 
exercise, there were no differences in symptoms of exertional chest pain, exercise-induced 
myocardial ischemia or the Duke Treadmill Score between groups (P>0.05; Table 3). Although 
there was an interaction between groups and exercise duration (Interaction: P=0.048; Table 3), 
post hoc testing indicated that there were no significant differences in exercise duration between 
groups (P>0.05). In exercisers, the time between the GXT and the vascular assessment was 
similar between patients with and without CMD (P>0.05; Table 3).  
Prior to the adjustment for pharmaceutical use and fasting, the RHI and LnRHI were 
lower in patients with confirmed CMD compared to patients without CMD (P<0.01), and 
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exercisers demonstrated an attenuated RHI and LnRHI compared to non-exercisers (P<0.01; 
Table 4). Augmentation indices (AI and AI@75bpm) were similar between patients with and 
without CMD (P>0.05), and exercisers demonstrated an attenuated AI compared to non-
exercisers (P<0.01), while the AI@75bpm were similar between exercisers and non-exercisers 
(P>0.05, Table 4). After adjusting for pharmaceutical use and fasting, the RHI and LnRHI were 
still lower in patients with confirmed CMD compared to patients without CMD (P<0.01; Figure 
2). Further, RHI and LnRHI were still lower in exercisers compared to non-exercisers (P<0.01; 
Figure 2). There were no exercise or condition effects in the adjusted AI and AI@75bpm 
(P>0.05; Figure 3).  
Correlations of the time between tests and the LnRHI were conducted for exercisers with 
CMD, exercisers without CMD, and for all exercisers combined. In exercisers with confirmed 
CMD (n=15), there was a positive correlation (r=0.57, P<0.05), and in exercisers without CMD 
(n=11) a trend towards a positive correlation (r=0.55, P=0.08) was observed. Since there was no 
difference when comparing the correlation coefficients between patients with and without CMD 
(P=0.95), all exercisers were grouped and a positive correlation was observed (r=0.54, P<0.01; 
Figure 4). 
Covariate analysis of the adjusted model (data not shown) found that there were no 
effects of anti-hypertensive medication use, anti-cholesterol medication use, or fasted state on 
RHI, LnRHI, or AI@75bpm (P>0.05). Further, anti-hypertensive medication use and anti-
cholesterol medication use had no effect on AI (P>0.05), however, fasted state increased AI 
(P=0.046).  
 
Discussion 
 The effect of acute exercise on peripheral microvascular function in patients with 
coronary microvascular dysfunction (CMD) was previously unknown. First, patients with CMD 
demonstrated impaired coronary and peripheral microvascular function. Second, consistent with 
studies in conduit arteries and healthy participants (224), acute exercise impaired microvascular 
function in patients with and without CMD. Third, contrary to our hypothesis, acute maximal 
exercise impaired peripheral microvascular function equally in patients with and without CMD. 
Several studies have investigated the relationship between coronary microvascular 
function (using measurements of coronary flow) and RHPAT in cardiac patients. For example, 
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patients with abnormal coronary blood flow responses to acetylcholine and patients with non-
obstructive coronary artery disease have lower RHI (197, 198).  However, most recently, RHI 
was not associated with coronary flow reserve (CFR) in women with chest pain and non-
obstructive coronary arteries (199). When additionally considering coronary resistance (i.e. 
IMR), a stronger predictor of adverse cardiac events (189) and a more hemodynamically stable 
measure of coronary microvascular function (200), our results suggest that patients with 
abnormal coronary function demonstrate an impaired RHI.   
In the current study, all suspected CMD patients who exercised prior to RHPAT testing 
exhibited an attenuation of RHI and LnRHI, supporting previous work that peripheral endothelial 
function is attenuated following acute exercise (224, 242, 243). This was further supported by 
our observation that LnRHI was correlated with the time between tests in all patients. During 
high intensity exercise, oxidative stress is increased (244, 245), facilitating the reduction in 
endothelial function following acute exercise in health (246, 247) and disease (242). Since 
oxidative stress has been shown to be elevated in patients with CMD (248), we had hypothesized 
that baseline impairments in peripheral endothelial function in CMD patients would exacerbate 
post-exercise microvascular function compared to the non-CMD group, yet this was not 
observed. We suggest that measurements of oxidative stress should be added to future 
longitudinal investigations of the effect of exercise in CMD.   
The use of RHPAT is a clinically appealing method of measuring peripheral 
microvascular function, given that RHPAT assessments are relatively cost efficient, operator 
independent, possess objective and automated analyses (240), and are highly reproducible (249, 
250). However, the standardizations for RHPAT assessments have not been determined in health 
or disease. Our data shows that RHI and LnRHI were not influenced by pharmacological use or 
fasting. In particular, the observation that fasting did not demonstrate a significant influence is 
important for CMD patients since fasting prior to exercise could lead to hypoglycemia during 
their clinical visit and/or exercise stress test, given the high prevalence of diabetes mellitus (251, 
252). Further, our data suggests that RHI and LnRHI are reduced by standard exercise stress 
testing, reducing the accuracy of RHPAT assessments in patients with suspected CMD. Notably, 
patients without CMD that exercised appeared to have similar peripheral microvascular function 
as patients with CMD who did not exercise. Therefore, our data suggests that when RHPAT 
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testing is performed in a clinical setting, exercise stress testing should not be performed 
beforehand.  
Contrary to previous reports (171, 174), the present study observed that measures of 
arterial stiffness were similar in patients with and without CMD. Several studies observed that 
both the aortic augmentation index (174) and the carotid artery augmentation index (171) were 
associated with the CFR response to intravenous adenosine in patients with CMD, implying that 
arterial stiffness in the large, mainly elastic arteries, is elevated in patients with CMD. In the 
current study, augmentation index was obtained from the finger microvasculature using the 
EndoPAT device, suggesting that arterial stiffness in the peripheral vasculature is similar in both 
conditions. Further, the validity of the augmentation indices obtained from the EndoPAT device 
have yet to be compared to a gold-standard measurement such as applanation tonometry of 
conduit vessels. 
We acknowledge several important considerations. First, this study was a cross-sectional 
study design. To fully elucidate the relationship between RHI and acute exercise, a repeated 
measures study design should be completed. However, to date, no study has investigated the 
relationship between RHI and exercise in patients with CMD, and these results provide strong 
evidence to continue this work. Second, since the time delay between the RHPAT assessment 
and the coronary reactivity testing was ~5 months, we cannot rule out that peripheral vascular 
function could have been altered within this time period due to changes in lifestyle or severity of 
condition, despite medication use being unchanged. Thirdly, although patients with and without 
CMD had similar exercise tolerances during the GXT (suggesting equal levels of 
cardiorespiratory fitness), this study did not objectively assess physical activity or oxygen 
consumption via a full cardiopulmonary exercise test. Lower physical activity has been linked 
with impaired endothelial function following acute exercise (243) potentially influencing our 
results. Therefore, future studies should obtain accurate measurements of fitness using 
accelerometry and oxygen consumption. 
In conclusion, these data support our previous work that patients with confirmed CMD 
have impaired peripheral microvascular function compared to patients without CMD, and are the 
first data to suggest that exercise stress testing impairs peripheral microvascular function in all 
patients with suspected CMD equally. Further, in exercisers with and without CMD, there was a 
positive relationship between peripheral microvascular function and the time between exercise 
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testing and vascular assessment. Lastly, while longitudinal studies are recommended in the future 
to confirm our findings, we recommend that RHPAT measurements in patients with suspected 
CMD should not be conducted after exercise has been performed. 
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Figure Legends 
 
Figure 1: Schematic of patients recruited from the Cardiovascular Integrative Physiology Clinic 
(CVIP) at Southlake Regional Health Centre. RHPAT: Reactive Hyperemia Peripheral Arterial 
Tonometry; GXT Graded Exercise Test. 
 
Figure 2: Adjusted reactive hyperemia index (RHI; A) and natural logarithm of the RHI 
(LnRHI; B) in patients with or without coronary microvascular dysfunction (CMD). Patients 
were separated into groups who did and did not exercise prior to vascular assessment. White bars 
represent patients without CMD. Grey bars represent patients with CMD. Non-EX indicates 
patients who did not exercise prior to assessment. Mean ± SD. 
 
Figure 3: Adjusted augmentation index (AI; A) and augmentation index at 75 bpm (AI@75bpm; 
B) in patients with or without coronary microvascular dysfunction (CMD). Patients were 
separated into groups who did and did not exercise prior to vascular assessment. White bars 
represent patients without CMD. Grey bars represent patients with CMD. Non-EX indicates 
patients who did not exercise prior to assessment. Mean ± SD. 
 
Figure 4: Correlation between the natural logarithm of the reactive hyperemia index (LnRHI) 
and the time between the graded exercise stress test and the vascular assessment in patients who 
exercised prior to the vascular assessment. Black circles represent patients without coronary 
microvascular dysfunction (CMD). White triangles represent patients with CMD. 
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Tables 
 
Table 1: Anthropometrics, hemodynamics, medication use, and fasted state in patients with or 
without coronary microvascular dysfunction (CMD). 
 
    No CMD    CMD  
    Non-EX  Exercisers  Non-EX  Exercisers  
n    16  11   26  15 
Sex, male, n (%)  5 (31)  4 (36)   10 (38) 7 (47)   
Age (years)   54 ± 12 55 ± 17  62 ± 13 57 ± 8   
Height (m)   1.66 ± 0.11 1.71 ± 0.07  1.67 ± 0.08 1.69 ± 0.14  
Weight (kg)   77.5 ± 20.7 83.7 ± 20.4  78.4 ± 13.8 80.1 ± 16.3  
BMI (kg/m2)   28 ± 6  29 ± 7   28 ± 4  28 ± 3  
SBP (mmHg)   119 ± 15 121 ± 12  126 ± 15 121 ± 9  
DBP (mmHg)   75 ± 9  75 ± 9   77 ± 9  75 ± 7   
Resting HR (bpm)  62 ± 9  71 ± 12*  65 ± 13 71 ±14*  
Medication use, n (%) 
 Anti-Hypertensive† 9 (56)  6 (55)   22 (85) 12 (80)  
 Anti-Cholesterol†  7 (44)  2 (18)   17 (65) 10 (67)  
Fasted, n (%)   3 (19)  0 (0)   7 (27)  3 (20)   
Non-EX: Non-Exercisers; CMD: Coronary Microvascular Dysfunction; SBP: Systolic Blood 
Pressure; DBP: Diastolic Blood Pressure; HR: Heart Rate; BMI: Body Mass Index. * indicates a 
significant exercise effect. † indicates a significant effect of CMD. Mean ± SD. 
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Table 2: Coronary flow and resistance responses to coronary infusions of adenosine and 
acetylcholine in patients with or without coronary microvascular dysfunction (CMD) undergoing 
coronary reactivity testing. 
 
    No CMD    CMD     
    Non-EX  Exercisers  Non-EX  Exercisers  
Adenosine  
IMR   14.1 ± 3.6 17.4 ± 4.8  23.7 ± 12.5 29.0 ± 14.1 
CFR   4.4 ± 2.0 3.1 ± 1.0  2.8 ± 1.9 3.0 ± 1.2  
Acetylcholine  
IMR   19.9 ± 5.2 17 ± 4.6  41.2 ± 19.7 45.8 ± 23.4  
CFR   2.9 ± 1.8 3.2 ± 0.9  1.5 ± 0.7 2.2 ± 1.8 
Non-EX: Non-Exercisers; CMD: Coronary Microvascular Dysfunction; CFR: Coronary Flow 
Reserve; IMR: Index of Microvascular Resistance. Mean ± SD.
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Table 3: Symptoms-limited maximal exercise testing data in patients with or without coronary 
microvascular dysfunction (CMD). 
 
    No CMD    CMD     
    Non-EX  Exercisers  Non-EX  Exercisers 
n    11  11   21  15 
Time between test (mins)   72 ± 33    68 ± 29  
Exercise duration (mins) 8.91 ± 2.06 6.92 ± 2.68  7.11 ± 3.15 8.13 ± 2.57  
Chest pain symptoms (%) 2 (18)  6 (55)   10 (48) 6 (40)   
ST Depression (%)  7 (64)  7 (64)   11 (52) 7 (47)   
DTS    3 ± 5  1 ± 5   1 ± 7  2 ± 5    
Non-EX: Non-Exercisers; CMD: Coronary Microvascular Dysfunction; DTS: Duke Treadmill 
Score. No significant effect of exercise or CMD for all variables (All P>0.05). Mean ± SD. 
Count (%).  
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Table 4: Unadjusted reactive hyperemia index (RHI), natural logarithm of the RHI (LnRHI), 
augmentation index (AI), and augmentation index at 75 bpm (AI@75bpm) in patients with or 
without coronary microvascular dysfunction (CMD). Patients were separated into groups who 
did and did not exercise prior to vascular assessment. Mean ± SD.  
 
    No CMD    CMD     
    Non-EX  Exercisers  Non-EX  Exercisers 
RHI†    2.43 ± 0.55 1.95 ± 0.41*  1.96 ± 0.55 1.67 ±  0.30*  
LnRHI†   0.86 ± 0.23 0.65 ± 0.21*  0.64 ± 0.26 0.50 ± 0.17*  
AI    25 ± 21 13 ± 19*  23 ± 25 11 ± 18*  
AI@75bpm   17 ± 19 11 ± 15  17 ± 25 8 ± 16   
Non-EX: Non-Exercisers; CMD: Coronary Microvascular Dysfunction; RHI: Reactive 
Hyperemia Index; LnRHI: Natural logarithm of the RHI; AI: Augmentation Index; AI@75bpm: 
Augmentation Index at 75 bpm. * indicates a significant exercise effect. † indicates a significant 
effect of CMD. Mean ± SD.  
 
 
 
 
 
